<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">20752</article-id><article-id pub-id-type="doi">10.7554/eLife.20752</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Decreased microRNA levels lead to deleterious increases in neuronal M2 muscarinic receptors in Spinal Muscular Atrophy models</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-66750"><name><surname>O'Hern</surname><given-names>Patrick J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7633-2779</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66751"><name><surname>do Carmo G. Gonçalves</surname><given-names>Inês</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66752"><name><surname>Brecht</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78430"><name><surname>López Soto</surname><given-names>Eduardo Javier</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66753"><name><surname>Simon</surname><given-names>Jonah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66754"><name><surname>Chapkis</surname><given-names>Natalie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78431"><name><surname>Lipscombe</surname><given-names>Diane</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66755"><name><surname>Kye</surname><given-names>Min Jeong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-15998"><name><surname>Hart</surname><given-names>Anne C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7239-4350</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Neuroscience</institution>, <institution>Brown University</institution>, <addr-line><named-content content-type="city">Providence</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Institute of Human Genetics</institution>, <institution>University of Cologne</institution>, <addr-line><named-content content-type="city">Cologne</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><label>3</label><institution>Brown Institute for Brain Science</institution>, <addr-line><named-content content-type="city">Providence</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hobert</surname><given-names>Oliver</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Columbia University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>anne_hart@brown.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>05</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e20752</elocation-id><history><date date-type="received"><day>17</day><month>08</month><year>2016</year></date><date date-type="accepted"><day>01</day><month>04</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, O'Hern et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>O'Hern et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-20752-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.20752.001</object-id><p>Spinal Muscular Atrophy (SMA) is caused by diminished Survival of Motor Neuron (SMN) protein, leading to neuromuscular junction (NMJ) dysfunction and spinal motor neuron (MN) loss. Here, we report that reduced SMN function impacts the action of a pertinent microRNA and its mRNA target in MNs. Loss of the <italic>C. elegans</italic> SMN ortholog, SMN-1, causes NMJ defects. We found that increased levels of the <italic>C. elegans</italic> Gemin3 ortholog, MEL-46, ameliorates these defects. Increased MEL-46 levels also restored perturbed microRNA (miR-2) function in <italic>smn-1(lf)</italic> animals. We determined that miR-2 regulates expression of the <italic>C. elegans</italic> M2 muscarinic receptor (m2R) ortholog, GAR-2. GAR-2 loss ameliorated <italic>smn-1(lf)</italic> and <italic>mel-46(lf)</italic> synaptic defects. In an SMA mouse model, m2R levels were increased and pharmacological inhibition of m2R rescued MN process defects. Collectively, these results suggest decreased SMN leads to defective microRNA function <italic>via</italic> MEL-46 misregulation, followed by increased m2R expression, and neuronal dysfunction in SMA.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.001">http://dx.doi.org/10.7554/eLife.20752.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.20752.002</object-id><title>eLife digest</title><p>Spinal muscular atrophy is a genetic disease that causes muscles to gradually weaken. In people with the disease, the nerve cells that control the movement of muscles – called motor neurons – deteriorate over time, hindering the person’s mobility and shortening their life expectancy. Spinal muscular atrophy is usually caused by genetic faults affecting a protein called SMN (which is short for “Survival of motor neuron”) and recent research suggested that disrupting this protein alters the function of short pieces of genetic material called microRNAs. However, the precise role that microRNAs play in the disease and their connection to the SMN protein was not clear.</p><p>MicroRNAs interfere with the production of proteins by disrupting molecules called messenger RNAs, which are temporary strings of genetic code that carry the instructions for making protein. By disrupting messenger RNAs, microRNAs can delay or halt the production of specific proteins. This is an important part of the normal behavior of a cell, but disturbing the activity of microRNAs can lead to an unwanted rise or fall in crucial proteins.</p><p>O’Hern et al. made use of engineered nematode worms and mice that share genetic features with spinal muscular atrophy patients, including disruption of the gene responsible for producing the SMN protein. These animal models of the disease were used to examine the relationship between decreased SMN levels and microRNAs in motor neurons. The experiments showed that reduced SMN activity affects a specific microRNA, which in turn causes motor neurons to produce more of a protein called m2R. This protein is a receptor for a molecule, called acetylcholine, which motor neurons use to send signals to muscle cells.</p><p>Increased m2R may be detrimental to motor neurons. As such, O’Hern et al. decreased m2R protein activity to determine whether this could reverse the defects in motor neurons that arise in the animal models of the disease. Indeed, blocking this receptor rescued some of the defects seen in the animal models, supporting the link to spinal muscular atrophy.</p><p>Several treatments that block m2R are already available to treat other conditions. As such, the next step is to determine whether these existing treatments are able to protect mice models of spinal muscular atrophy against muscle deterioration or increase their lifespan. If successful, this could open new avenues for the development of treatments in people.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.002">http://dx.doi.org/10.7554/eLife.20752.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>SMA</kwd><kwd>SMN</kwd><kwd>Gemin3</kwd><kwd>microRNA</kwd><kwd>GAR-2</kwd><kwd>m2R</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd><italic>C. elegans</italic></kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Spinal Muscular Atrophy Program Project</institution></institution-wrap></funding-source><award-id>P01 NS066888</award-id><principal-award-recipient><name><surname>Hart</surname><given-names>Anne C</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>NS066888</award-id><principal-award-recipient><name><surname>Hart</surname><given-names>Anne C</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>KY96/1-1</award-id><principal-award-recipient><name><surname>Kye</surname><given-names>Min Jeong</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000894</institution-id><institution>Spinal Muscular Atrophy Foundation</institution></institution-wrap></funding-source><award-id>SAH1516</award-id><principal-award-recipient><name><surname>Kye</surname><given-names>Min Jeong</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Universität zu Köln</institution></institution-wrap></funding-source><award-id>152/2014</award-id><principal-award-recipient><name><surname>Kye</surname><given-names>Min Jeong</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>F31NS089201</award-id><principal-award-recipient><name><surname>O'Hern</surname><given-names>Patrick J</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>2T32MH020068-11</award-id><principal-award-recipient><name><surname>O'Hern</surname><given-names>Patrick J</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>5T32MH020068-12</award-id><principal-award-recipient><name><surname>O'Hern</surname><given-names>Patrick J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In invertebrate and vertebrate models of Spinal Muscular Atrophy, diminished SMN protein causes Gemin3-dependent decreases in microRNA function, leading to upregulated M2 muscarinic receptor and deleterious consequences.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease and the leading genetic cause of infant death in the US (<xref ref-type="bibr" rid="bib12">Cusin et al., 2003</xref>; <xref ref-type="bibr" rid="bib68">Pearn, 1978</xref>). SMA is caused by homozygous deletion or mutation of the <italic>SMN1 (Survival Motor Neuron 1)</italic> gene, resulting in reduced Survival of Motor Neuron (SMN) protein levels (<xref ref-type="bibr" rid="bib50">Lefebvre et al., 1995</xref>). SMN expression is ubiquitous, but particularly essential for motor neuron survival (<xref ref-type="bibr" rid="bib51">Lefebvre et al., 1997</xref>). Disease severity, as well as spinal cord α-MN dysfunction and degeneration, correlates with the extent of SMN loss (<xref ref-type="bibr" rid="bib51">Lefebvre et al., 1997</xref>). Understanding why SMN loss impairs function should offer insight into SMA and may reveal therapeutic targets. SMN is conserved across species (<xref ref-type="bibr" rid="bib60">Miguel-Aliaga et al., 1999</xref>). Studies of various SMA models suggest a role for SMN in several cellular processes including snRNP assembly (<xref ref-type="bibr" rid="bib30">Golembe et al., 2005</xref>; <xref ref-type="bibr" rid="bib96">Yong et al., 2002</xref>), messenger RNA (mRNA) transport (<xref ref-type="bibr" rid="bib23">Fallini et al., 2011</xref>), and local translation (<xref ref-type="bibr" rid="bib15">Dimitriadi et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Kye et al., 2014</xref>). SMN function, however, has not been linked definitively to MN degeneration or synaptic transmission defects caused by SMN loss.</p><p>microRNAs (miRNAs) are non-coding RNAs that often repress protein translation, by a mechanism that requires miRNA binding to the 3’UTR of mRNA targets. Disruption of the miRNA pathway in spinal MNs leads to severe degeneration (<xref ref-type="bibr" rid="bib33">Haramati et al., 2010</xref>). SMN loss alters levels and/or activity of specific miRNAs (<xref ref-type="bibr" rid="bib33">Haramati et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Kye et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Valsecchi et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Wang et al., 2014</xref>), but the cellular mechanisms leading to altered miRNA expression and/or function are unknown. The RNA helicase Gemin3 associates with both SMN and RNA-induced silencing complex components (<xref ref-type="bibr" rid="bib8">Charroux et al., 1999</xref>; <xref ref-type="bibr" rid="bib38">Höck et al., 2007</xref>; <xref ref-type="bibr" rid="bib37">Hutvágner and Zamore, 2002</xref>; <xref ref-type="bibr" rid="bib59">Meister et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Mourelatos et al., 2002</xref>; <xref ref-type="bibr" rid="bib63">Murashov et al., 2007</xref>). Gemin3 and SMN levels decrease concomitantly, suggestive of a functional link (<xref ref-type="bibr" rid="bib24">Feng et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Helmken et al., 2003</xref>).</p><p>We took advantage of the <italic>C. elegans</italic> SMA model to examine the connection between SMN, Gemin3, and miRNA function. <italic>SMN1</italic>, <italic>Gemin3,</italic> and multiple miRNA pathway components are conserved in <italic>C. elegans</italic> (<xref ref-type="bibr" rid="bib32">Grishok et al., 2001</xref>; <xref ref-type="bibr" rid="bib60">Miguel-Aliaga et al., 1999</xref>; <xref ref-type="bibr" rid="bib61">Minasaki et al., 2009</xref>). Loss-of-function (lf) mutations in <italic>smn-1</italic>, the <italic>C. elegans</italic> ortholog of <italic>SMN1</italic>, cause behavioral and morphological abnormalities, premature death, and sterility (<xref ref-type="bibr" rid="bib4">Briese et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Sleigh et al., 2011</xref>). <italic>smn-1(lf)</italic> animals also have neuromuscular junction (NMJ) defects, suggesting a functional role for SMN-1 in MNs (<xref ref-type="bibr" rid="bib4">Briese et al., 2009</xref>). MNs in <italic>smn-1(lf)</italic> animals do not die, likely because of their short lifespan. However, <italic>smn-1(lf)</italic> neuromuscular defects may correspond to the early stages of SMA pathogenesis, characterized by NMJ dysfunction prior to MN degeneration (<xref ref-type="bibr" rid="bib60">Miguel-Aliaga et al., 1999</xref>; <xref ref-type="bibr" rid="bib97">Yoshida et al., 2015</xref>). We find that the <italic>C. elegans</italic> Gemin3 ortholog, MEL-46, is perturbed by SMN-1 loss, impacting miR-2 suppression of the M2 muscarinic receptor ortholog, GAR-2 (<xref ref-type="bibr" rid="bib49">Lee et al., 2000</xref>). Across species in SMA mouse models, we find decreased levels of miR-128, a potential miR-2 ortholog, and increased expression of the GAR-2 ortholog, m2R. Notably, m2R inhibition ameliorates axon outgrowth defects in MNs from a SMA mouse model, consistent with our results in <italic>C. elegans</italic>.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MEL-46 (Gemin3) is required for NMJ function</title><p>The <italic>C. elegans</italic> Gemin3 ortholog is MEL-46. Homozygous loss of <italic>smn-1</italic> or <italic>mel-46</italic> results in lethality (<xref ref-type="bibr" rid="bib4">Briese et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Miguel-Aliaga et al., 1999</xref>), but maternal loading of <italic>smn-1</italic> or <italic>mel-46</italic> mRNA and protein allows many homozygous, loss of function animals to survive into the last larval stage, called L4 (<xref ref-type="bibr" rid="bib60">Miguel-Aliaga et al., 1999</xref>; <xref ref-type="bibr" rid="bib61">Minasaki et al., 2009</xref>). Loss of <italic>smn-1</italic> results in neuromuscular defects including decreased pharyngeal pumping rates, followed by overtly altered locomotion and subsequent death (<xref ref-type="bibr" rid="bib4">Briese et al., 2009</xref>). Like <italic>smn-1</italic> loss in L4 stage animals, we found that <italic>mel-46(tm1739)</italic> homozygous loss of function animals had severely decreased pharyngeal pumping rates. Pharyngeal pumping was restored to normal rates in <italic>mel-46(tm1739)</italic> animals using a previously described, broadly expressed <italic>mel-46</italic> rescue array (also referred to as [<italic>mel-46(+)</italic>#1]), which utilizes the <italic>mel-46</italic> promoter (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) (<xref ref-type="bibr" rid="bib61">Minasaki et al., 2009</xref>). <italic>mel-46</italic> partial loss of function alleles, <italic>yt5</italic> and <italic>ok3760</italic>, also caused pumping defects as did global <italic>mel-46</italic> RNA interference (<italic>RNAi</italic>) or cholinergic neuron-specific <italic>mel-46(RNAi)</italic> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–E</xref>). We conclude that MEL-46 is necessary for normal neuromuscular function.<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.003</object-id><label>Figure 1.</label><caption><title>Decreased MEL-46 function in <italic>C. elegans</italic> results in defective NMJ signaling.</title><p>(<bold>a</bold>) <italic>mel-46(tm1739)</italic> animals had reduced pharyngeal pumping rates <italic>versus</italic> wild type (N2) control animals. Defects were fully rescued by global expression of MEL-46 behind its own promoter ([<italic>mel-46(+)#1</italic>]). Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two-tailed. (<bold>b</bold>) <italic>mel-46(tm1739)</italic> animals paralyzed more slowly when exposed to aldicarb, an acetylcholinesterase inhibitor. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mel-46(tm1739),</italic> and <italic>mel-46(tm1739);[mel-46(+)#1</italic>] early larval stage L4 animals. Reintroduction of <italic>mel-46</italic> restored normal aldicarb sensitivity. Log-rank test. (<bold>c</bold>) Cholinergic neuron-specific <italic>mel-46(RNAi)</italic> causes resistance to aldicarb. Time course for paralysis on 1.5 mM aldicarb for empty(<italic>RNAi</italic>), <italic>smn-1(RNAi)</italic>, <italic>mel-46(RNAi)</italic>, and <italic>goa-1(RNAi)</italic> young adult animals. Animals sensitive to RNAi in only cholinergic neurons (XE1581) were fed bacteria expressing double-stranded RNA (dsRNA) against <italic>mel-46</italic>, <italic>smn-1,</italic> or <italic>goa-1</italic> (positive control). Control animals were fed bacteria expressing an empty vector control: empty(<italic>RNAi</italic>). Data set previously published without <italic>mel-46(RNAi)</italic> (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Log-rank test. (<bold>d</bold>) <italic>mel-46(tm1739)</italic> animals had reduced RFP::SNB-1 (synaptobrevin). Percent change from wild type (N2) control for RFP::SNB-1 in the dorsal cord of <italic>mel-46(tm1739)</italic> and <italic>mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] animals for ‘punctaanalyzer’ parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to wild type; shading indicates significant change for <italic>mel-46(tm1739) versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>]. Mann-Whitney <italic>U</italic>-test, two-tailed. Expression of <italic>mel-46</italic> rescued RFP::SNB-1 puncta width defects in <italic>mel-46(tm1739)</italic> animals (wild type <italic>versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.82); <italic>mel-46(tm1739) versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.03), rescued SNB-1 puncta intensity defects (wild type <italic>versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.85; <italic>mel-46(tm1739) versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.005) and partially ameliorated SNB-1 puncta linear density defects (wild type <italic>versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.0004); <italic>mel-46(tm1739) versus mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.0001). (<bold>h–j</bold>) Representative images of RFP::SNB-1 expressed in the dorsal cord of cholinergic DA MNs for wild type, <italic>mel-46(tm1739),</italic> and <italic>mel-46(tm1739);</italic>[<italic>mel-46(+)#1</italic>] animals. These images were taken as part of data collection. Scale bar, 5 μm. For statistical analyses in all figures: *<italic>p</italic>≤0.05, **<italic>p</italic>&lt;0.01, ***<italic>p</italic>&lt;0.001. A helpful summary of <italic>C. elegans</italic> phenotypes reported throughout this article for selected loss of function alleles can be found in <xref ref-type="supplementary-material" rid="SD16-data">Supplementary file 1</xref>. Additional information on <italic>C. elegans</italic> strains used in <xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig6">6</xref> is provided in <xref ref-type="supplementary-material" rid="SD17-data">Supplementary file 2A</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.003">http://dx.doi.org/10.7554/eLife.20752.003</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.20752.004</object-id><label>Figure 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title><p>Raw data and statistical analysis that correspond to RFP::SNB-1 localization analysis in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.004">http://dx.doi.org/10.7554/eLife.20752.004</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.005</object-id><label>Figure 1—figure supplement 1.</label><caption><title>MEL-46(Gemin3) is necessary for proper NMJ function.</title><p>(<bold>a</bold>) Schematic representation of the predicted <italic>mel-46</italic> gene. Large arrow indicates the direction of translation. Also shown are the positions of the <italic>yt5</italic> G to A transition, the <italic>tm1739</italic> deletion and the <italic>ok3760</italic> complex substitution, for which the inserted sequence is indicated (<xref ref-type="bibr" rid="bib61">Minasaki et al., 2009</xref>). (<bold>b</bold>) <italic>mel-46(yt5)</italic> animals had reduced pharyngeal pumping rates <italic>versus</italic> wild type (N2) control. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>c</bold>) <italic>mel-46(ok3760)</italic> animals had reduced pharyngeal pumping rates <italic>versus</italic> wild type (N2) control. Mean ± SEM; <italic>t</italic>-test, two tailed. This data was collected alongside data in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. (<bold>d</bold>) Animals sensitive to RNAi in all tissues (KP3948) fed bacteria expressing double-stranded RNA (dsRNA) against <italic>mel-46</italic> had reduced pharyngeal pumping rates <italic>versus</italic> control animals fed bacteria expressing an empty vector control. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>e</bold>) Animals sensitive to RNAi in only cholinergic neurons (XE1581) fed bacteria expressing double-stranded RNA (dsRNA) against <italic>mel-46</italic> had reduced pharyngeal pumping rates <italic>versus</italic> control animals fed bacteria expressing an empty vector control. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>f</bold>) <italic>mel-46(yt5)</italic> animals were resistant to the acetylcholinesterase inhibitor, aldicarb. Broad expression of MEL-46 with [<italic>mel-46(+)#3</italic>], which uses the <italic>mel-46</italic> promoter, did not significantly restore <italic>mel-46(yt5)</italic> aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mel-46(yt5),</italic> and <italic>mel-46(yt5);[mel-46(+)#3]</italic> early larval stage L4 animals. Log-rank test. (<bold>g</bold>) <italic>mel-46(ok3760)</italic> animals were resistant to the acetylcholinesterase inhibitor, aldicarb. Time course for paralysis on 1 mM aldicarb for wild type (N2) and <italic>mel-46(ok3760)</italic> young adult animals. Log-rank test. This data was collected alongside data in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. (<bold>h</bold>) GABA neuron-specific <italic>mel-46</italic> RNAi or <italic>smn-1</italic> RNAi results in aldicarb hypersensitivity. Time course for paralysis on 1 mM aldicarb for empty(<italic>RNAi</italic>), <italic>smn-1(RNAi)</italic>, <italic>mel-46(RNAi)</italic>, and <italic>unc-25(RNAi)</italic> animals. Animals sensitive to RNAi in only GABAergic neurons (XE1375) were fed bacteria expressing double-stranded RNA (dsRNA) against <italic>mel-46, smn-1,</italic> or <italic>unc-25</italic> (positive control). Control animals were fed bacteria expressing an empty vector control: empty(<italic>RNAi</italic>). Log-rank test. For all statistical analyses in figure supplements: *<italic>p</italic>≤0.05, **<italic>p</italic>&lt;0.01, ***<italic>p</italic>&lt;0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.005">http://dx.doi.org/10.7554/eLife.20752.005</ext-link></p><p><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.20752.006</object-id><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title><p>Raw data and statistical analysis that correspond to pumping and aldicarb resistance assays in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.006">http://dx.doi.org/10.7554/eLife.20752.006</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig1-figsupp1-v1"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.007</object-id><label>Figure 1—figure supplement 2.</label><caption><title>MEL-46(Gemin3) loss causes increased APT-4(AP2 α-adaptin) linear density.</title><p>(<bold>a</bold>) <italic>mel-46(tm1739)</italic> animals had increased APT-4 (AP2 α-adaptin) linear density. Percent change from wild type control for APT-4 in the dorsal nerve cord of <italic>mel-46(tm1739)</italic> animals for ‘punctaanalyzer’ parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Mann-Whitney <italic>U</italic>-test, two-tailed. (<bold>b–c</bold>) Representative images of APT-4::GFP in the dorsal nerve cord of cholinergic DA MNs of wild type and <italic>mel-46(tm1739)</italic> animals. These images were taken as part of data collection. Scale bar, 5 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.007">http://dx.doi.org/10.7554/eLife.20752.007</ext-link></p><p><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.20752.008</object-id><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title><p>Raw data and statistical analysis that correspond to RFP::SNB-1 localization analysis in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.008">http://dx.doi.org/10.7554/eLife.20752.008</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig1-figsupp2-v1"/></fig></fig-group></p><p>SMN-1 is required for normal NMJ function in <italic>C. elegans</italic> cholinergic MNs (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Aldicarb is an acetylcholinesterase inhibitor that leads to acetylcholine accumulation in the NMJ and consequently, paralysis (<xref ref-type="bibr" rid="bib54">Mahoney et al., 2006</xref>). The time course of aldicarb-induced paralysis was slowed by decreased SMN-1 activity (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). We tested if a decrease in MEL-46 function causes similar resistance to aldicarb and found that <italic>mel-46</italic> loss of function resulted in aldicarb resistance across multiple alleles (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F and G</xref>), reminiscent of <italic>smn-1</italic> loss. Reintroduction of <italic>mel-46</italic> using the [<italic>mel-46(+)</italic>#1] rescue array restored aldicarb sensitivity in <italic>mel-46(tm1739)</italic> animals. Tissue-specific knock-down of <italic>mel-46</italic> in cholinergic neurons resulted in aldicarb resistance, thus confirming that MEL-46 function is required in cholinergic neurons, as is SMN-1 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). We also showed that knock-down of <italic>mel-46</italic> or <italic>smn-1</italic> in inhibitory GABAergic neurons resulted in aldicarb hypersensitivity (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). Our findings, taken together with previous work, suggest that MEL-46 and SMN-1 are required in both cholinergic and GABAergic neurons for normal NMJ function.</p><p><italic>smn-1</italic> loss causes changes in presynaptic protein localization (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Do similar changes occur in <italic>mel-46(tm1739)</italic> animals? We evaluated localization of presynaptic proteins SNB-1 (synaptobrevin) and APT-4 (AP2 α-adaptin) in cholinergic dorsal A-type (DA) MNs of <italic>mel-46(tm1739)</italic> animals (<xref ref-type="bibr" rid="bib7">Ch'ng et al., 2008</xref>; <xref ref-type="bibr" rid="bib76">Sieburth et al., 2005</xref>). SNB-1 is a v-SNARE protein required for SV exocytosis, while APT-4 associates with clathrin-coated endocytic vesicles (<xref ref-type="bibr" rid="bib43">Kamikura and Cooper, 2006</xref>; <xref ref-type="bibr" rid="bib65">Nonet et al., 1998</xref>). In the dorsal cord, cholinergic DA MNs do not have presynaptic inputs; they form <italic>en passant</italic> presynaptic connections in a punctate pattern (<xref ref-type="bibr" rid="bib7">Ch'ng et al., 2008</xref>; <xref ref-type="bibr" rid="bib93">White et al., 1976</xref>). Three parameters were measured to evaluate fluorescently labeled SNB-1 and APT-4 localization to presumptive synapses: puncta width (μm), intensity (AU), and linear density (puncta/μm), as previously described (<xref ref-type="bibr" rid="bib45">Kim et al., 2008</xref>). Loss of <italic>smn-1</italic> or <italic>mel-46</italic> resulted in similar SNB-1 synaptic localization defects: decreased SNB-1 puncta width, intensity and linear density (<xref ref-type="fig" rid="fig1">Figure 1D–G</xref>) (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Loss of <italic>smn-1</italic> leads to decreased APT-4 puncta width and intensity, but increased linear density (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). <italic>mel-46(tm1739)</italic> animals also had increased APT-4 linear density, but no changes in puncta width or intensity compared to controls (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–C</xref>). Therefore, decreased <italic>mel-46</italic> causes synaptic protein defects that overlap partially with defects observed when SMN-1 levels decrease. Given the similarities between SMN-1 and MEL-46 loss in aldicarb resistance, decreased pharyngeal pumping rates, and defective synaptic protein localization, we decided to explore whether SMN-1 and MEL-46 act in common pathways required for NMJ function.</p></sec><sec id="s2-2"><title>Perturbed MEL-46 (Gemin3) function likely contributes to synaptic defects in <italic>smn-1(lf)</italic> animals</title><p>MEL-46 might act together with or downstream of SMN-1 in pathways necessary for NMJ function. To test these and other possibilities, we generated integrated multicopy transgenic lines expressing GFP-tagged MEL-46 expressed under control of the <italic>unc-17</italic> cholinergic-specific promoter (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). MEL-46::GFP was found in both the cell bodies and processes of neurons. No obvious changes were seen in cytoplasmic MEL-46::GFP, leading us to evaluate localization of MEL-46::GFP in MN dorsal cord processes in <italic>smn-1(ok355)</italic> animals. Because <italic>ok355</italic> deletion in <italic>smn-1</italic> leads to a complete loss of function, <italic>smn-1(ok355)</italic> animals were maintained over an <italic>hT2</italic> balancer and sterile <italic>smn-1(ok355)</italic> homozygous progeny carry some maternally-loaded SMN-1 protein (<xref ref-type="bibr" rid="bib4">Briese et al., 2009</xref>). We found that MEL-46::GFP localizes to small granular structures in dorsal cord processes in control (<italic>smn-1(+)</italic>) and <italic>smn-1(ok355)</italic> animals. Our finding is consistent with previous work showing that Gemin3 localizes to granular structures in mammalian neurites; Gemin3 co-localizes with SMN in 50–60% of these granules, along with multiple mRNAs (<xref ref-type="bibr" rid="bib84">Todd et al., 2010a</xref>, <xref ref-type="bibr" rid="bib85">2010b</xref>; <xref ref-type="bibr" rid="bib98">Zhang et al., 2006</xref>). In <italic>smn-1(ok355)</italic> animals, we found that the density of MEL-46::GFP-positive granular structures was doubled compared to <italic>smn-1(+)</italic> controls (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>). Furthermore, the mean intensity of MEL-46::GFP fluorescence and the maximum fluorescence for each sample were decreased in <italic>smn-1(ok355)</italic> animals (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). These results suggest that decreased SMN-1 leads to MEL-46 mislocalization in cholinergic MN processes and diminished MEL-46 levels in granules. Our findings suggest that SMN-1 impairs MEL-46 function, which could contribute to <italic>smn-1(ok355)</italic> synaptic defects (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). To test this hypothesis, we increased <italic>mel-46</italic> gene dosage in <italic>smn-1(ok355)</italic> animals using the [<italic>mel-46(+)#1</italic>] rescue array and showed that this ameliorated <italic>smn-1(ok355)</italic> aldicarb resistance defects (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). We also showed that increasing <italic>mel-46</italic> specifically in cholinergic neurons, using the cholinergic-specific <italic>unc-17</italic> (ACh) promoter in an integrated array, referred to as [ACh::<italic>mel-46</italic>::GFP], rescued <italic>smn-1(ok355)</italic> aldicarb resistance (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B and C</xref>). The aldicarb resistance observed with broad expression of <italic>mel-46</italic> in control animals (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) was not observed when we overexpressed <italic>mel-46</italic> in cholinergic neurons only. Under this condition we observed mild hypersensitivity in one integrated line (referred to as [ACh::<italic>mel-46::</italic>GFP#1]) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>) and no difference from control animals in a second line (referred to as [ACh::<italic>mel-46::</italic>GFP#2]) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). It is possible that high levels of MEL-46 in cholinergic neurons cause aldicarb hypersensitivity, whereas broad overexpression of MEL-46 may impact NMJ function independent of cholinergic neurons. Taken together, our results suggest that loss of SMN-1 negatively impacts MEL-46 function, resulting in perturbed NMJ signaling. Our finding is consistent with observations in humans that reduced human SMN levels result in Gemin3 downregulation (<xref ref-type="bibr" rid="bib24">Feng et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Helmken et al., 2003</xref>),<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.009</object-id><label>Figure 2.</label><caption><title>MEL-46 localization and levels are perturbed in <italic>smn-1(lf)</italic> animals.</title><p>(<bold>a</bold>) Illustration: <italic>mel-46</italic> was tagged with GFP at the C-terminus and expression was driven by the cholinergic (ACh) <italic>unc-17</italic> promoter. Two lines were generated by UV integration. (<bold>b</bold>) <italic>smn-1(ok355)</italic> animals exhibited mislocalization and reduction of MEL-46::GFP in dorsal cord processes of cholinergic neurons. MEL-46::GFP localizes to granular punctate structures in dorsal cord processes. Percent change from <italic>smn-1(+)</italic> control for MEL-46::GFP in the dorsal cord of <italic>smn-1(ok355)</italic> animals for ImageJ parameters: puncta density (puncta/area), puncta intensity (AU), and puncta size (pixels/puncta). The ImageJ analysis was used instead of the ‘punctaanalyzer’ program since MEL-46::GFP had a scattered non-linear pattern in <italic>smn-1(ok355)</italic> animals; a linear pattern is necessary for accurate ‘punctaanalyzer’ analysis. Asterisks denote significance compared to wild type. Mann-Whitney <italic>U</italic>-test, two-tailed. (<bold>c–d</bold>) Representative images of MEL-46::GFP in dorsal cord cholinergic DA MN processes for control <italic>smn-1</italic>(<italic>+</italic>) and <italic>smn-1</italic>(<italic>ok355</italic>) animals. These images were taken as part of data collection. Scale bar, 5 μm. (<bold>e</bold>) Increasing expression of <italic>mel-46</italic> rescued <italic>smn-1(ok355)</italic> aldicarb response defects. Time course for paralysis on 1 mM aldicarb for <italic>smn-1(+)</italic>, <italic>smn-1(ok355), smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>], and <italic>smn-1(+)</italic>;[<italic>mel-46(+)#1</italic>] early larval stage L4 animals. <italic>smn-1(+);</italic>[<italic>mel-46(+)#1</italic>] animals were resistant to paralysis by aldicarb. Log-rank test. (<bold>f</bold>) Increasing <italic>mel-46</italic> rescued <italic>smn-1(ok355)</italic> RFP::SNB-1 synaptic localization defects. Percent change from <italic>smn-1(+)</italic> control for RFP::SNB-1 in the dorsal cord of <italic>smn-1(ok355), smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>], and <italic>smn-1(+);</italic>[<italic>mel-46(+)#1</italic>] animals for ‘punctaanalyzer’ parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to <italic>smn-1(+)</italic> control; shading indicates significant difference from <italic>smn-1(ok355);[mel-46(+)#1].</italic> Mann-Whitney <italic>U</italic>-test, two-tailed. Expression of <italic>mel-46</italic> restored RFP::SNB-1 puncta width defects (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.05; <italic>smn-1(ok355) versus smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.001), rescued SNB-1 puncta intensity defects (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.035; <italic>smn-1(ok355) versus smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.0004), but did not rescue SNB-1 puncta linear density defects (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.036; <italic>smn-1(ok355) versus smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>] <italic>p=</italic>0.19). (<bold>G–J</bold>) Representative images of cholinergic DA MN RFP::SNB-1 in the dorsal nerve cord of <italic>smn-1(+), smn-1(ok355)</italic> and <italic>smn-1(ok355);</italic>[<italic>mel-46(+)#1</italic>]. These images were taken as part of data collection. Scale bar, 5 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.009">http://dx.doi.org/10.7554/eLife.20752.009</ext-link></p><p><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.20752.010</object-id><label>Figure 2—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p>Raw data and statistical analysis that correspond to MEL-46::GFP localization, aldicarb resistance assays, and RFP::SNB-1 localization analysis in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.010">http://dx.doi.org/10.7554/eLife.20752.010</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20752-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.011</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Expressing <italic>mel-46</italic> restores neuronal defects in <italic>smn-1(lf)</italic> animals.</title><p>(<bold>a</bold>) Decreased SMN-1 resulted in a 21% decrease in maximum MEL-46::GFP fluorescence in dorsal cord DA motor neuron processes. Histogram of maximum fluorescence (AU) for <italic>smn-1(+)</italic> and <italic>smn-1(ok355)</italic> animals. <italic>t</italic>-test. p&lt;0.01. (<bold>b</bold>) Increasing cholinergic expression using the <italic>unc-17</italic> (ACh) promoter of <italic>mel-46</italic> partially rescued <italic>smn-1(ok355)</italic> aldicarb response defects. Time course for paralysis on 1 mM aldicarb for <italic>smn-1(+)</italic>, <italic>smn-1(ok355), smn-1(ok355);</italic>[ACh<italic>::mel-46::GFP #1</italic>], and <italic>smn-1(+)</italic>;[ACh<italic>::mel-46::GFP #1</italic>] early larval stage L4 animals. Log-rank test. (<bold>c</bold>) Increasing cholinergic expression of <italic>mel-46</italic> resulted in rescue of <italic>smn-1(ok355)</italic> aldicarb response defects. Time course for paralysis on 1 mM aldicarb for <italic>smn-1(+)</italic>, <italic>smn-1(ok355), smn-1(ok355);</italic>[ACh<italic>::mel-46::GFP #1</italic>], and <italic>smn-1(+)</italic>;[ACh<italic>::mel-46::GFP #1</italic>] early larval stage L4 animals. <italic>smn-1(+)</italic>;[ACh<italic>::mel-46::GFP #1</italic>] were hypersensitive to paralysis by aldicarb. Log-rank test. (<bold>c–d</bold>) The same MEL-46::GFP integrated lines were used to evaluate levels and localization in <xref ref-type="fig" rid="fig2">Figure 2B–D</xref>. Despite rescue <italic>smn-1(ok355)</italic> aldicarb resistance, these animals expressing cholinergic MEL-46::GFP still exhibit MEL-46 mislocalization likely leading to decreased function. This rescue may occur because enough MEL-46::GFP is expressed to overcome mislocalization-related functional deficits. (<bold>d</bold>) <italic>smn-1(ok355)</italic> animals had reduced pharyngeal pumping rates <italic>versus smn-1(+)</italic> control animals; defects were not rescued by increasing <italic>mel-46</italic> using the [<italic>mel-46)+)#1</italic>] array. <italic>smn-1(+);</italic> [<italic>mel-46(+)#1</italic>] animals had pharyngeal pumping rates indistinguishable from <italic>smn-1(+)</italic> controls. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two-tailed. (<bold>e</bold>) Broad expression of MEL-46 using the <italic>mel-46</italic> promoter ameliorated the APT-4 (AP2 α-adaptin) linear density defect in <italic>smn-1(ok355)</italic> animals. Percent change from <italic>smn-1(+)</italic> control for APT-4 in the dorsal cord of <italic>smn-1(ok355)</italic> and <italic>smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] animals for ‘punctaanalyzer’ parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance <italic>versus smn-1(+)</italic> control; shading indicates <italic>smn-1(ok355)</italic> is significantly different from <italic>smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>]. Mann-Whitney <italic>U</italic>-test, two-tailed. Expression of MEL-46 did not rescue APT-4 puncta width (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] <italic>p=</italic>0.006; <italic>smn-1(ok355) versus smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] <italic>p=</italic>0.48), did not rescue APT-4 total puncta intensity (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] <italic>p=</italic>0.002; <italic>smn-1(ok355) versus smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] <italic>p=</italic>0.27), but ameliorated APT-4 puncta linear density (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] <italic>p=</italic>0.93; <italic>smn-1(ok355) versus smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>] <italic>p=</italic>0.05).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.011">http://dx.doi.org/10.7554/eLife.20752.011</ext-link></p><p><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.20752.012</object-id><label>Figure 2—figure Supplement 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title><p>Raw data and statistical analysis that correspond to MEL-46::GFP localization, APT-4::GFP localization analysis, aldicarb resistance and pumping assays in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.012">http://dx.doi.org/10.7554/eLife.20752.012</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig2-figsupp1-v1"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.013</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Expressing <italic>mel-46</italic> does not increase SMN-1 levels.</title><p>(<bold>a</bold>) Illustration: <italic>smn-1(rt280)</italic> was generated by CRISPR-mediated insertion of GFP upstream of <italic>smn-1</italic> exon 1. (<bold>b</bold>) Increasing MEL-46 expression using the [<italic>mel-46(+)#2</italic>] array led to decreased GFP::SMN-1 fluorescence. Quantification of mean <italic>smn-1(rt280)</italic> GFP fluorescence in wild type and [<italic>mel-46(+)#2</italic>] backgrounds. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>c</bold>) Representative images of <italic>smn-1(rt280)</italic> GFP expression in wild type and [<italic>mel-46(+)#2</italic>] larval stage L4 animals. Scale bar, 50 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.013">http://dx.doi.org/10.7554/eLife.20752.013</ext-link></p><p><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.20752.014</object-id><label>Figure 2—figure Supplement 2—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title><p>Raw data and statistical analysis that correspond to GFP::SMN-1 quantification in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.014">http://dx.doi.org/10.7554/eLife.20752.014</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig2-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig2-figsupp2-v1"/></fig></fig-group></p><p>The interdependency we report, between SMN-1 and MEL-46 levels, may be specific to particular tissues and/or neural circuits. For example, pharyngeal pumping rate defects were not ameliorated in <italic>smn-1(ok355)</italic> animals by increased <italic>mel-46</italic> levels ([<italic>mel-46(+)</italic>#1] rescue array, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>), suggesting a privileged relationship between SMN-1 and MEL-46 in cholinergic NMJ signaling. Increasing <italic>mel-46</italic> did rescue <italic>smn-1(ok355)</italic> synaptic protein localization defects. Using the [<italic>mel-46(+)</italic>#1] rescue array, we rescued <italic>smn-1(ok355)</italic> defective SNB-1 puncta width and intensity to normal levels, but did not ameliorate linear density defects (<xref ref-type="fig" rid="fig2">Figure 2F–J</xref>). Notably, increased <italic>mel-46</italic> in an <italic>smn-1(+)</italic> control background did not increase SNB-1 levels, suggesting that <italic>mel-46-</italic>induced up-regulation of SNB-1 is specifically beneficial in a <italic>smn-1(ok355)</italic> background. Increasing <italic>mel-46</italic> with a second broadly-expressed <italic>mel-46</italic> rescue array line, [<italic>mel-46(+)</italic>#2], also restored APT-4 puncta linear density to normal levels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>), without rescuing other metrics. These results are consistent with the aldicarb/NMJ functional rescue studies presented here and suggest increasing <italic>mel-46</italic> improves neuromuscular signaling in <italic>smn-1(ok355)</italic> animals by partially restoring levels and localization of synaptic proteins. Furthermore, these results suggest that <italic>mel-46</italic> may act with or downstream of <italic>smn-1</italic> in a pathway essential for NMJ function.</p><p>Alternatively, we considered the possibility that increasing <italic>mel-46</italic> stabilizes maternally-loaded SMN-1 protein and mRNA, a scenario which could also explain <italic>mel-46</italic> rescue of <italic>smn-1(ok355)</italic> NMJ function. Since mammalian Gemin3 directly binds SMN (<xref ref-type="bibr" rid="bib8">Charroux et al., 1999</xref>), increasing MEL-46 (Gemin3) might decrease the rate of SMN-1 loss. To test this possibility, we used CRISPR/Cas9-targeted genome editing to insert GFP coding sequences at the N-terminus of <italic>smn-1</italic> on chromosome I, resulting in fluorescent SMN-1 protein (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>) (<xref ref-type="bibr" rid="bib14">Dickinson et al., 2015</xref>). The GFP-tagged protein was functional; animals were viable and fertile. We found that increasing <italic>mel-46</italic> using the [<italic>mel-46(+)</italic>#2] rescue array did not increase GFP::SMN-1 levels, but unexpectedly caused a modest overall decrease (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B and C</xref>). It therefore seems unlikely that <italic>smn-1(ok355)</italic> rescue by increased <italic>mel-46</italic> is due to stabilization of maternally-loaded SMN-1. Using the same CRISPR-based method, we were unable to tag endogenous <italic>smn-1</italic> on balancer chromosomes necessary for maintaining the <italic>smn-1(ok355)</italic> line. This approach would have allowed us to examine the effects of MEL-46 overexpression on the stability of maternally-loaded SMN-1 in <italic>smn-1(ok355)</italic> animals. Therefore, although we cannot rule out stability of maternally-loaded SMN-1 as a contributing factor, the large effect that decreased SMN-1 has on MEL-46 localization favors a mechanism in which MEL-46 overexpression rescues <italic>smn-1(ok355)</italic> defects, at least in part, by restoring MEL-46 functional deficits in this background.</p></sec><sec id="s2-3"><title><italic>C.elegans</italic> miR-2 is required for NMJ function</title><p>The pathways in MNs downstream of SMN and Gemin3 that are linked to SMA are unknown. Here, we consider a role for these two proteins in miRNA regulation. As mammalian Gemin3 co-localizes and co-purifies with RISC pathway components (<xref ref-type="bibr" rid="bib38">Höck et al., 2007</xref>; <xref ref-type="bibr" rid="bib37">Hutvágner and Zamore, 2002</xref>; <xref ref-type="bibr" rid="bib59">Meister et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Mourelatos et al., 2002</xref>; <xref ref-type="bibr" rid="bib63">Murashov et al., 2007</xref>), we considered a role for miRNA regulation in NMJ function. miRNA miR-2 is enriched in neurons, expressed at all developmental stages, and predicted to regulate expression of many proteins involved in neuronal development and function (<xref ref-type="bibr" rid="bib55">Marco et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Martinez et al., 2008</xref>). We hypothesized that miR-2 is necessary for proper NMJ function and that it might be perturbed by loss of either SMN-1 or MEL-46. To test this possibility, we first examined the aldicarb response of <italic>mir-2(lf)</italic> animals. Two different deletion alleles, <italic>gk259</italic> and <italic>n4108</italic>, caused resistance to aldicarb paralysis compared to wild type animals (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). This defect was partially rescued by expressing miR-2 under the control of a the <italic>unc-17</italic> (ACh) cholinergic neuron-specific promoter (referred to as ([ACh::<italic>mir-2(+)</italic>]) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Loss of miR-2 also resulted in a mild pharyngeal pumping defect (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Taken together, we conclude that miR-2 is required in cholinergic neurons for proper NMJ signaling.<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.015</object-id><label>Figure 3.</label><caption><title>miR-2 is required in cholinergic neurons for proper NMJ function.</title><p>(<bold>a</bold>) <italic>mir-2(gk259)</italic> animals were resistant to paralysis by aldicarb. Expression of miR-2 behind the <italic>unc-17</italic> (ACh) cholinergic promoter partially restored <italic>mir-2(gk259)</italic> sensitivity to aldicarb compared to transgenesis controls expressing GFP behind the same promoter. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mir-2(gk259), mir-2(gk259);</italic>[<italic>ACh::mir-2(+)</italic>] and <italic>mir-2(gk259);</italic>[<italic>ACh::GFP</italic>] young adult animals. Log-rank test. (<bold>b</bold>) <italic>mir-2(gk259)</italic> animals had increased RFP::SNB-1 (synaptobrevin) linear density. Percent change from wild type (N2) control for RFP::SNB-1 in the dorsal nerve cord of <italic>mir-2(gk259)</italic> animals for ‘punctaanalyzer’ parameters: puncta width (μm), intensity (AU), and linear density (number/μm). <italic>t</italic>-test, two-tailed. (<bold>c–d</bold>) Representative images of cholinergic DA MN RFP::SNB-1 in the dorsal cord of wild type and <italic>mir-2(gk259)</italic> animals. These images were taken as part of data collection. Scale bar, 5 μm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.015">http://dx.doi.org/10.7554/eLife.20752.015</ext-link></p><p><supplementary-material id="SD7-data"><object-id pub-id-type="doi">10.7554/eLife.20752.016</object-id><label>Figure 3—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p>Raw data and statistical analysis that correspond to aldicarb resistance assays and RFP::SNB-1 localization analysis in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.016">http://dx.doi.org/10.7554/eLife.20752.016</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig3-v1"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.017</object-id><label>Figure 3—figure supplement 1.</label><caption><title>miR-2 is required for NMJ function.</title><p>(<bold>a</bold>) <italic>mir-2(n4108)</italic> animals were resistant to the acetylcholinesterase inhibitor, aldicarb. Time course for paralysis on 1 mM aldicarb for wild type (N2) and <italic>mir-2(n4108)</italic> young adult animals. Log-rank test. (<bold>b</bold>) <italic>mir-2(gk259)</italic> animals had reduced pharyngeal pumping rates <italic>versus</italic> wild type control. Mean ± SEM; <italic>t</italic>-test, two-tailed. (<bold>c</bold>) <italic>mir-2(gk259)</italic> SYD-2 (α-liprin) levels were indistinguishable from wild type (N2). Percent change from wild type control for SYD-2 in the dorsal nerve cord of <italic>mir-2(gk259)</italic> animals for ‘punctaanalyzer’ parameters: average puncta width (μm), total intensity (AU), and linear density (number/μm). <italic>t</italic>-test, two-tailed. (<bold>d</bold>) <italic>mir-2(lf)</italic> had reduced expression of ITSN-1 (DAP160/Intersectin). Percent change from wild type (N2) control for ITSN-1 in the dorsal nerve cord of <italic>mir-2(gk259)</italic> and <italic>mir-2(n4108)</italic> animals as above. <italic>t</italic>-test, two-tailed. (<bold>e–f</bold>) Representative images of ITSN-1::GFP expressed in the dorsal nerve cord of cholinergic DA motor neurons for wild type and <italic>mir-2(n4108)</italic> animals. These images were taken as part of data collection. Scale bar, 5 μm. (<bold>g</bold>) <italic>mir-2(gk259)</italic> and <italic>mir-2(n4108)</italic> animals had reduced APT-4 (AP2 α-adaptin) levels. Percent change from wild type (N2) control for the APT-4 in <italic>mir-2(gk259)</italic> animals as above. <italic>t</italic>-test, two-tailed. (<bold>h–i</bold>) Representative images of cholinergic DA motor neuron APT-4::GFP in the dorsal cord of wild type (N2) and <italic>mir-2(gk259)</italic> animals. These images were taken as part of data collection.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.017">http://dx.doi.org/10.7554/eLife.20752.017</ext-link></p><p><supplementary-material id="SD8-data"><object-id pub-id-type="doi">10.7554/eLife.20752.018</object-id><label>Figure 3—figure Supplement 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title><p>Raw data and statistical analysis that correspond to SYD-2::GFP localization analysis, ITSN-1::GFP localization analysis, APT-4::GFP analysis, aldicarb resistance and pumping assays in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.018">http://dx.doi.org/10.7554/eLife.20752.018</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig3-figsupp1-v1"/></fig></fig-group></p><p>As a first step towards evaluating how miR-2 loss impacts cholinergic MN presynaptic function, we examined the effects of miR-2 loss on localization of presynaptic proteins in DA MNs. Four fluorescently-tagged presynaptic proteins were examined: SNB-1 (synaptobrevin), SYD-2 (α-liprin), ITSN-1 (DAP160/Intersectin), and APT-4 (AP2 α-adaptin). Analysis of tagged SNB-1 in <italic>mir-2(gk259)</italic> animals revealed increased SNB-1 puncta linear density, but no change in puncta width or intensity compared to wild type animals (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Additionally, <italic>mir-2(gk259)</italic> animals were indistinguishable from wild type control animals with respect to SYD-2 synaptic localization for all metrics analyzed (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), suggesting that pre-synaptic active zones are unchanged in number and size; thus, synaptic changes are likely not the result of altered active zone number or size (<xref ref-type="bibr" rid="bib99">Zhen and Jin, 1999</xref>). ITSN-1 puncta width and intensity, but not linear density, were decreased in <italic>mir-2(gk259)</italic> and <italic>mir-2(n4108),</italic> animals compared to wild type controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D–F</xref>). Finally, both <italic>mir-2(gk259)</italic> and <italic>mir-2(n4108)</italic> had decreased APT-4 puncta width, intensity, and linear density (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G–I</xref>). ITSN-1, similar to APT-4, is involved in vesicle recycling at the NMJ (<xref ref-type="bibr" rid="bib88">Wang et al., 2008</xref>). Together with results from aldicarb resistance studies, our results suggest that loss of miR-2 results in synaptic dysfunction at the NMJ, consistent with decreased cholinergic synaptic release (<xref ref-type="bibr" rid="bib7">Ch'ng et al., 2008</xref>; <xref ref-type="bibr" rid="bib76">Sieburth et al., 2005</xref>). Additionally, we observed considerable overlap between synaptic protein localization defects resulting from miR-2 loss with those of <italic>smn-1(ok355)</italic> animals (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>), a finding consistent with miR-2 and SMN-1 acting in partially redundant pathways at the NMJ.</p></sec><sec id="s2-4"><title><italic>C.elegans</italic> miR-2 targets <italic>gar-2</italic> mRNA in cholinergic neurons</title><p>To address mechanistically how miR-2 loss impacts NMJ function, we searched for mRNA targets of miR-2. Canonically, miRNA loss results in overexpression of direct mRNA targets (<xref ref-type="bibr" rid="bib21">Elbashir et al., 2001</xref>). Since miR-2 loss leads to aldicarb resistance, loss of the target(s) is expected to cause hypersensitivity to aldicarb. Following a literature search for genes whose loss of function results in hypersensitivity, we selected the following genes with putative miR-2 3’UTR binding sites for study: <italic>gar-2</italic>, <italic>dbl-1</italic>, <italic>sek-1</italic>, and <italic>vab-2</italic> (<xref ref-type="bibr" rid="bib41">Jan et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Lewis et al., 2005</xref>; <xref ref-type="bibr" rid="bib66">Paraskevopoulou et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Reczko et al., 2012</xref>; <xref ref-type="bibr" rid="bib87">Vashlishan et al., 2008</xref>). Loss of a <italic>bona fide</italic> target gene is predicted to suppress aldicarb resistance caused by miR-2 loss. Therefore, we crossed a deletion allele for each gene into the <italic>mir-2(gk259)</italic> background. Loss of any of these four genes suppressed <italic>mir-2(gk259)</italic> to some extent, but <italic>gar-2(ok520),</italic> which contains a large deletion removing <italic>gar-2</italic> exons 6 and 7, resulted in the most complete suppression, thus suggesting that GAR-2 acts downstream of miR-2 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–C</xref>). GAR-2 is a G protein-coupled acetylcholine receptor orthologous to the mammalian M2 muscarinic receptor (m2R) (<xref ref-type="bibr" rid="bib49">Lee et al., 2000</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.019</object-id><label>Figure 4.</label><caption><title>miR-2 binds the gar-2 3’UTR and represses GAR-2 translation.</title><p>(<bold>a</bold>) Loss of m2R ortholog, GAR-2, suppressed aldicarb response defects of animals lacking <italic>mir-2(gk259). gar-2(ok520)</italic> animals were hypersensitive to paralysis by aldicarb. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mir-2(gk259), gar-2(ok520)</italic> and <italic>mir-2(gk259);gar-2(ok520)</italic> young adult animals. Log-rank test. (<bold>b</bold>) Schematic representation of changes made to the endogenous <italic>gar-2</italic> 3’UTR using CRISPR. For the wild type control (<italic>gar-2</italic> UTRwt<sup>C</sup>), the miR-2 binding site remained intact, however, a C&gt;T PAM site change was made. For the experimental condition (<italic>gar-2</italic> UTRscr<sup>C</sup>), the miR-2 binding site was scrambled in addition to the C&gt;T PAM site alteration. (<bold>c</bold>) <italic>gar-2</italic>(<italic>rt318)</italic>, referred to as <italic>gar-2</italic> UTRscr<sup>C</sup>, animals were resistant to the acetylcholinesterase inhibitor, aldicarb, compared to <italic>gar-2(rt317),</italic> referred to as <italic>gar-2</italic> UTRwt<sup>C</sup>. Time course for paralysis on 1 mM aldicarb for young adult animals. Log-rank test. (<bold>d</bold>) Scrambling the predicted endogenous <italic>gar-2</italic> 3’UTR miR-2 binding site increased <italic>gar-2</italic> messenger RNA levels. Quantification of <italic>gar-2</italic> mRNA levels in young adult <italic>gar-2</italic> UTRwt<sup>C</sup> and <italic>gar-2</italic> UTRscr<sup>C</sup> animals. <italic>t-</italic>test, two-tailed (n = 4 for <italic>gar-2</italic> UTRwt<sup>C</sup> and <italic>gar-2</italic> UTRscr<sup>C</sup>). (<bold>e</bold>) Reporter constructs used to assess miR-2 regulation of <italic>gar-2</italic> 3’UTR in cholinergic neurons: <italic>rtIs56</italic> (<italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt) and <italic>rtIs57</italic> or <italic>rtIs58</italic> (<italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr). <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt construct contains the <italic>unc-17</italic> promoter expressing NLS::GFP upstream of the <italic>gar-2</italic> 3’UTR, which has a predicted miR-2 binding site. Red text indicates intact seed region. <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr is the same construct with the predicted miR-2 binding site scrambled identically to the sequence in <italic>gar-2</italic> UTRscr<sup>C</sup> animals. (<bold>f</bold>) Representative images of <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt expression in cholinergic neurons of wild type (N2) and <italic>mir-2(gk259)</italic> larval stage L4 animals. Scale bar, 50 μm. (<bold>g</bold>) Representative images of <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr (<italic>rtIs57</italic>) expression in cholinergic neurons of wild type (N2) and <italic>mir-2(gk259)</italic> larval stage L4 animals. (<bold>h</bold>) Ratio representation of mean GFP fluorescence for wild type and <italic>mir-2(gk259)</italic> animals. <italic>t</italic>-test, two-tailed. Ratio was calculated by dividing the mean GFP fluorescence of <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt for each genotype by the corresponding mean GFP fluorescence of <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr for that genotype. UTRwt represents mean fluorescence for each genotype expressing the <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt reporter, while UTRscr represents mean fluorescence for each genotype expressing the <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr control reporter. Error bars represent the cumulative SEM for each genotype across transgenes. (see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). (<bold>i</bold>) <italic>gar-2</italic> transcript levels did not increase in a <italic>mir-2</italic> loss of function background. Quantification of <italic>gar-2</italic> mRNA levels in young adult <italic>mir-2(gk259)</italic> animals compared to wild type (N2) controls. <italic>t-test</italic>, two-tailed (n = 4 for <italic>mir-2(gk259)</italic> and N2).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.019">http://dx.doi.org/10.7554/eLife.20752.019</ext-link></p><p><supplementary-material id="SD9-data"><object-id pub-id-type="doi">10.7554/eLife.20752.020</object-id><label>Figure 4—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>Raw data and statistical analysis that correspond to aldicarb resistance assays, qPCR quantification, and GFP reporter analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.020">http://dx.doi.org/10.7554/eLife.20752.020</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20752-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.021</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Loss of predicted miR-2 mRNA targets suppresses <italic>mir-2(lf)</italic> aldicarb resistance.</title><p>(<bold>a</bold>) Loss of DBL-1 suppressed <italic>mir-2(gk259)</italic> aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mir-2(n4108), mir-2(n4108);dbl-1(nk3),</italic> and <italic>dbl-1(nk3)</italic> young adult animals. Log-rank test. (<bold>b</bold>) Loss of SEK-1 suppressed <italic>mir-2(gk259)</italic> aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mir-2(n4108), mir-2(n4108);sek-1(km4),</italic> and <italic>sek-1(km4)</italic> young adult animals. Log-rank test. (<bold>c</bold>) Loss of VAB-2 suppressed <italic>mir-2(gk259)</italic> aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), <italic>mir-2(n4108), mir-2(n4108);vab-2(ju1),</italic> and <italic>vab-2(ju1)</italic> young adult animals. Log-rank test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.021">http://dx.doi.org/10.7554/eLife.20752.021</ext-link></p><p><supplementary-material id="SD10-data"><object-id pub-id-type="doi">10.7554/eLife.20752.022</object-id><label>Figure 4—figure Supplement 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title><p>Raw data and statistical analysis that correspond to aldicarb resistance assays in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.022">http://dx.doi.org/10.7554/eLife.20752.022</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig4-figsupp1-v1"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.023</object-id><label>Figure 4—figure supplement 2.</label><caption><title>miR-2 inhibits translation by binding the <italic>gar-2</italic> 3’UTR.</title><p>(<bold>a</bold>) Loss of <italic>miR-2</italic> results in increased expression of <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt. <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt mean GFP fluorescence in wild type (N2) and <italic>mir-2(gk259)</italic> backgrounds. Mean ± SEM; <italic>t</italic>-test, two-tailed. (<bold>b–c</bold>) Expression of <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr was indistinguishable in <italic>mir-2(gk259) versus</italic> wild type (N2) animals for two independent integrated lines. <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr mean GFP fluorescence in wild type (N2) and <italic>mir-2(gk259)</italic> backgrounds. Mean ± SEM; <italic>t</italic>-test, two-tailed. (<bold>d</bold>) Formula used to calculate the ratio and standard error of the mean (SEM) shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>. UTRwt represents mean fluorescence for each genotype expressing the <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt reporter, while UTRscr represents mean fluorescence for each genotype expressing the <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr control reporter. For SEM, <italic>s</italic> represents the standard deviation of the population and n represents the number of animals analyzed.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.023">http://dx.doi.org/10.7554/eLife.20752.023</ext-link></p><p><supplementary-material id="SD11-data"><object-id pub-id-type="doi">10.7554/eLife.20752.024</object-id><label>Figure 4—figure Supplement 2—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title><p>Raw data and statistical analysis that correspond to GFP reporter analysis in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.024">http://dx.doi.org/10.7554/eLife.20752.024</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig4-figsupp2-v1"/></fig></fig-group></p><p>To determine if miR-2 regulates GAR-2 expression directly, we examined the consequences of perturbing the putative miR-2 binding site in the <italic>gar-2</italic> 3’UTR. Using CRISPR/Cas9-targeted genome editing, we scrambled the 18 base pair <italic>gar-2</italic> 3’UTR region corresponding to the endogenous miR-2 binding site (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Compared to control animals (<italic>gar-2</italic> UTRwt<sup>C</sup>) carrying the disrupted PAM site mutation (C&gt;T), we found that animals with the scrambled miR-2 binding site (<italic>gar-2</italic> UTRscr<sup>C</sup>) were resistant to aldicarb, similar to miR-2 loss (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). To evaluate whether disruption of the miR-2 binding site influenced <italic>gar-2</italic> transcript levels, we compared <italic>gar-2</italic> mRNA levels in <italic>gar-2</italic> UTRscr<sup>C</sup> animals and <italic>gar-2</italic> UTRwt<sup>C</sup> controls and found a 40% increase in <italic>gar-2</italic> transcript in <italic>gar-2</italic> UTRscr<sup>C</sup> (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Disruption of the 3’UTR site likely inhibits binding of other miR-2 family members, possibly contributing to the effect we observe (<xref ref-type="bibr" rid="bib39">Ibáñez-Ventoso et al., 2008</xref>).</p><p>To test the effects of miR-2 loss on GAR-2 function in cholinergic neurons, we undertook in vivo GFP reporter analysis of GAR-2 expression. We generated a construct encoding GFP with a <italic>gar-2</italic> 3’UTR, whose expression is driven under the control of a cholinergic-specific promoter (referred to as <italic>unc-17p-</italic>ACh::GFP::<italic>gar-2</italic> 3’UTRwt). A second control version of the construct contained the same scrambled UTR sequence as used in <italic>gar-2</italic> UTRscr<sup>C</sup> animals (referred to as <italic>unc-17p-</italic>ACh::GFP::<italic>gar-2</italic> 3’UTRscr) (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Transgenic lines were created by multicopy insertion for each construct. Increased GFP levels were observed in <italic>mir-2(gk259)</italic> animals expressing the intact 3’UTR construct as compared to control animals (<xref ref-type="fig" rid="fig4">Figure 4F</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). Whereas, loss of the <italic>mir-2</italic> gene did not affect GFP levels in animals expressing the scrambled 3’UTR construct compared to control (<xref ref-type="fig" rid="fig4">Figure 4G</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B and C</xref>). To quantify impact of miR-2 on expression of these GFP reporters in various genetic backgrounds, we compared relative changes in GFP levels of transgenic lines using a ratiometric strategy; we determined GFP expression for lines carrying <italic>unc-17p-</italic>ACh::GFP::<italic>gar-2</italic> 3’UTRwt and compared these values to lines carrying <italic>unc-17p-</italic>ACh::GFP::<italic>gar-2</italic> 3’UTRscr in the same genetic background (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). By this method, we observed a ~13% increase in relative GFP expression associated with loss of miR-2 (<xref ref-type="fig" rid="fig4">Figure 4H</xref>), indicating that miR-2 directly suppresses translation of <italic>gar-2</italic> mRNA by binding the <italic>gar-2</italic> 3’UTR at this 3’UTR site. We also assessed the effect of miR-2 loss on <italic>gar-2</italic> transcript levels and found no significant difference in <italic>gar-2</italic> mRNA levels between wild type animals and <italic>mir-2(gk259)</italic> loss of function animals (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). These results, combined with our reporter data, suggest that miR-2 binds and inhibits <italic>gar-2</italic> mRNA translation, but does not reduce transcript levels. Previous studies have reported that miRNAs can influence protein synthesis of targets without destabilizing mRNA levels (<xref ref-type="bibr" rid="bib10">Cloonan, 2015</xref>; <xref ref-type="bibr" rid="bib75">Selbach et al., 2008</xref>).</p></sec><sec id="s2-5"><title>miR-2 suppression of <italic>gar-2</italic> is disrupted by smn-1 loss</title><p>Next, we determined if <italic>smn-1</italic> loss altered miR-2 regulation of the <italic>gar-2</italic> 3’UTR. Both GFP reporter transgenes were crossed into the <italic>smn-1(ok355)</italic> background. Using the same ratiometric strategy from <xref ref-type="fig" rid="fig4">Figure 4H</xref>, we observed a small increase in relative GFP reporter expression (~5%) in <italic>smn-1(ok355)</italic> animals compared to <italic>smn-1(+)</italic> controls (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). This finding suggested that <italic>smn-1(ok355)</italic> animals may have decreased miR-2 function and, as a consequence, an increase in GAR-2 translation. We showed above that increased <italic>mel-46</italic> levels ameliorates <italic>smn-1(ok355)</italic> NMJ defects (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), therefore we assessed the impact of increased <italic>mel-46</italic> on miR-2 activity using the [<italic>mel-46(+)</italic>#2] rescue array. In control <italic>smn-1(+)</italic> animals, increasing <italic>mel-46</italic> did not alter relative expression of the miR-2 GFP reporter. However, in <italic>smn-1(ok355)</italic> animals, increasing <italic>mel-46</italic> caused decreased relative reporter expression by ~15%, compared to <italic>smn-1(ok355)</italic> animals lacking the <italic>mel-46</italic> rescue array (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). These data suggest that MEL-46 overexpression decreases GAR-2 levels in <italic>smn-1(ok355)</italic> by increasing miR-2 activity.<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.025</object-id><label>Figure 5.</label><caption><title><italic>smn-1</italic> loss of function abrogated miR-2 repression of GAR-2 expression.</title><p>(<bold>a</bold>) Loss of <italic>smn-1</italic> caused a relative increase in <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt expression. Expressing <italic>mel-46</italic> using the broadly expressed [<italic>mel-46(+)#2</italic>] array decreased relative <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt expression in <italic>smn-1(ok355)</italic> animals. Ratio representation of mean GFP fluorescence for <italic>smn-1(+), smn-1(ok355), smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>], and <italic>smn-1(+);</italic>[<italic>mel-46(+)#2</italic>] animals. Mann-Whitney <italic>U</italic>-test, two-tailed. Ratio calculation was completed in the same manner as <xref ref-type="fig" rid="fig4">Figure 4H</xref> (see also <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>) (<bold>b</bold>) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty(<italic>RNAi</italic>), <italic>smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals relative to housekeeping miRNA miR-60. <italic>t-</italic>test, two-tailed (n = 6 for each condition). (<bold>c</bold>) <italic>gar-2</italic> transcript levels did not change when SMN-1 or MEL-46 levels decreased in neurons. Quantification of <italic>gar-2</italic> mRNA for empty(<italic>RNAi</italic>), <italic>smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals. <italic>t-</italic>test, two-tailed (n = 3 for each condition). (<bold>c–d</bold>) Animals sensitive to RNAi in only neurons (TU3401) were fed bacteria expressing double-stranded RNA (dsRNA) against <italic>mel-46</italic> or <italic>smn-1.</italic> Control animals were fed bacteria expressing an empty vector control: empty(<italic>RNAi</italic>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.025">http://dx.doi.org/10.7554/eLife.20752.025</ext-link></p><p><supplementary-material id="SD12-data"><object-id pub-id-type="doi">10.7554/eLife.20752.026</object-id><label>Figure 5—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.026">http://dx.doi.org/10.7554/eLife.20752.026</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.027</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Increasing MEL-46(Gemin3) ameliorates <italic>smn-1(lf)</italic> defective miR-2 activity.</title><p>(<bold>a</bold>) Expression of mean <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRscr (<italic>rtIs57</italic>) fluorescence was decreased in <italic>smn-1(ok355)</italic> compared to <italic>smn-1(+)</italic> control animals. Increasing MEL-46 levels using the [<italic>mel-46(+)#2</italic>] array did not alter expression <italic>versus smn-1(+)</italic> controls. Mean <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt fluorescence in <italic>smn-1(+), smn-1(ok355), smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>], and <italic>smn-1(+);</italic>[<italic>mel-46(+)#2</italic>] animals. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>b</bold>) Expression of mean <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt fluorescence was indistinguishable between <italic>smn-1(+)</italic> and <italic>smn-1(ok355)</italic> animals; increasing MEL-46 using the [<italic>mel-46(+)#2</italic>] array reduced expression <italic>versus</italic> control. Mean <italic>unc-17</italic>p-ACh::GFP::<italic>gar-2</italic> 3’UTRwt fluorescence in <italic>smn-1(+), smn-1(ok355), smn-1(ok355);</italic>[<italic>mel-46(+)#2</italic>], and <italic>smn-1(+);</italic>[<italic>mel-46(+)#2</italic>] animals. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>c</bold>) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty(<italic>RNAi</italic>), <italic>smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals relative to housekeeping gene <italic>act-1. t-</italic>test, two-tailed (n = 6 for each condition). (<bold>d</bold>) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty(<italic>RNAi</italic>), <italic>smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals relative to housekeeping rRNA 18s. <italic>t-</italic>test, two-tailed (n = 6 for each condition).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.027">http://dx.doi.org/10.7554/eLife.20752.027</ext-link></p><p><supplementary-material id="SD13-data"><object-id pub-id-type="doi">10.7554/eLife.20752.028</object-id><label>Figure 5—figure Supplement 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title><p>Raw data and statistical analysis that correspond to GFP reporter analysis and qPCR quantification in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.028">http://dx.doi.org/10.7554/eLife.20752.028</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig5-figsupp1-v1"/></fig></fig-group></p><p>Increased GAR-2 translation in animals lacking SMN-1 might be due to decreased mature miR-2 levels. To test this possibility, we used quantitative RT-PCR studies. After neuron-specific RNAi knock-down of either SMN-1 or MEL-46, we found decreases in mature miR-2 levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>), but no change in <italic>gar-2</italic> transcript levels (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). This result is consistent with our finding that <italic>gar-2</italic> transcript levels were unchanged in miR-2 complete loss conditions (<xref ref-type="fig" rid="fig4">Figure 4I</xref>), despite alterations in GFP reporter expression (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). These results suggest neuronal miR-2 levels are decreased when MEL-46 or SMN-1 levels decrease.</p><p>Collectively, our data above are consistent with a model where diminished SMN-1 leads to decreased miR-2 levels and activity, resulting in increased GAR-2 expression. Since M2 receptors inhibit synaptic release at cholinergic NMJs across species (<xref ref-type="bibr" rid="bib18">Dittman and Kaplan, 2008</xref>; <xref ref-type="bibr" rid="bib67">Parnas et al., 2005</xref>; <xref ref-type="bibr" rid="bib79">Slutsky et al., 2003</xref>), overexpression of these receptors in <italic>smn-1(ok355)</italic> MNs might contribute to the NMJ defects previously observed in these animals (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Sleigh et al., 2011</xref>). Furthermore, increased MEL-46/Gemin3 might have an ameliorative effect in animals lacking SMN-1 by stimulating miR-2 activity, thus decreasing GAR-2 levels and disinhibiting cholinergic release.</p></sec><sec id="s2-6"><title><italic>gar-2</italic> loss ameliorates <italic>smn-1(lf)</italic> neuromuscular defects</title><p>If increased GAR-2 levels exacerbate NMJ dysfunction in animals lacking SMN-1, then decreasing GAR-2 function should ameliorate the NMJ defects caused by <italic>smn-1</italic> loss of function. Loss of GAR-2 did not improve pharyngeal pumping rates in <italic>smn-1(ok355)</italic> animals (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), similar to our results in animals with increased <italic>mel-46</italic> levels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). However, similar to increasing <italic>mel-</italic>46, <italic>gar-2(ok520)</italic> restored normal response to aldicarb in both <italic>smn-1(ok355)</italic> and <italic>smn-1(rt248)</italic> animals (<xref ref-type="fig" rid="fig6">Figure 6A</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), consistent with improved NMJ function. The <italic>rt248 smn-1</italic> allele causes a frameshift and loss of SMN-1 function similar to <italic>ok355</italic> (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Additionally, <italic>gar-2(ok520)</italic> restored normal response to aldicarb in <italic>mel-46(tm1739)</italic> animals (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Our results indicate that decreasing GAR-2 likely improves presynaptic function in animals with decreased SMN-1 or MEL-46. Consistent with this conclusion, <italic>gar-2(ok520)</italic> also rescued numerous presynaptic protein localization defects caused by SMN-1 loss; SNB-1 puncta width, intensity and linear density defects were rescued in both <italic>smn-1(ok355)</italic> and <italic>smn-1(rt248)</italic> backgrounds (<xref ref-type="fig" rid="fig6">Figure 6C–6G</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D–H</xref>). GAR-2 loss in <italic>smn-1(+)</italic> control animals resulted in increased SNB-1 puncta width and intensity, but did not alter SNB-1 puncta linear density.<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.029</object-id><label>Figure 6.</label><caption><title>Loss of <italic>gar-2</italic> ameliorated <italic>smn-1(lf)</italic> NMJ defects.</title><p>(<bold>a</bold>) Loss of <italic>gar-2</italic> rescued <italic>smn-1(ok355)</italic> aldicarb response defect. Time course for paralysis on 1 mM aldicarb for <italic>smn-1(+)</italic>, <italic>smn-1(ok355), smn-1(ok355);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic> early larval stage L4 animals. Log-rank test. (<bold>b</bold>) Loss of <italic>gar-2</italic> rescued <italic>mel-46(tm1739)</italic> aldicarb response defect. Time course for paralysis on 1 mM aldicarb for <italic>mel-46(+)</italic>, <italic>mel-46(tm1739), mel-46(tm1739);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic> early larval stage L4 animals. Log-rank test. For these experiments, <italic>mel-46(tm1739)</italic> was maintained over the <italic>nT1</italic> balancer and therefore, control <italic>mel-46(+)</italic> animals were obtained as +/+ animals from +/<italic>nT1</italic> heterozygous mothers. (<bold>c</bold>) Loss of <italic>gar-2</italic> rescued <italic>smn-1(ok355)</italic> RFP::SNB-1 synaptic localization defects. <italic>gar-2</italic> loss in the <italic>smn-1(+)</italic> background resulted in increased RFP::SNB-1 puncta width and intensity. Percent change from <italic>smn-1(+)</italic> control for RFP::SNB-1 in the dorsal nerve cord of <italic>smn-1(ok355), smn-1(ok355);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic> animals for ‘punctaanalyzer’ parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to <italic>smn-1(+)</italic> control; shading indicates significant difference from <italic>smn-1(ok355);gar-2(ok520).</italic> Mann-Whitney <italic>U</italic>-test, two-tailed. Loss of <italic>gar-2</italic> rescued RFP::SNB-1 puncta width defects (<italic>smn-1(+)</italic> control animals <italic>versus smn-1(ok355);gar-2(ok520) p=</italic>0.76; <italic>smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=</italic>0.0001), restored SNB-1 puncta intensity (<italic>smn-1(+)</italic> control animals <italic>versus smn-1(ok355);gar-2(ok520) p=</italic>1.00; <italic>smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=</italic>0.0001) and rescued SNB-1 puncta linear density defects (<italic>smn-1(+)</italic> control animals <italic>versus smn-1(ok355);gar-2(ok520) p=</italic>0.08; <italic>smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=</italic>0.02). (<bold>d–g</bold>) Representative images of cholinergic DA MN RFP::SNB-1 in the dorsal nerve cord of <italic>smn-1(+), smn-1(ok355), smn-1(ok355);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic>. These images were taken as part of data collection. Scale bar, 5 μm. Figures D and G are also shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> since this control data was collected alongside both <italic>ok355</italic> and <italic>rt248</italic> RFP::SNB-1 data.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.029">http://dx.doi.org/10.7554/eLife.20752.029</ext-link></p><p><supplementary-material id="SD14-data"><object-id pub-id-type="doi">10.7554/eLife.20752.030</object-id><label>Figure 6—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title><p>Raw data and statistical analysis that correspond to RFP::SNB-1 localization analysis and aldicarb resistance assays in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.030">http://dx.doi.org/10.7554/eLife.20752.030</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-20752-fig6-v1"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.031</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Decreasing GAR-2(m2R) levels rescues NMJ defects in <italic>smn-1(lf)</italic> and <italic>mel-46(lf)</italic> animals.</title><p>(<bold>a</bold>) <italic>smn-1(ok355)</italic> animals had reduced pharyngeal pumping rates <italic>versus smn-1(+)</italic> control animals; defects were not rescued by loss of GAR-2. Mean ± SEM; Mann-Whitney <italic>U</italic>-test, two tailed. (<bold>b</bold>) Loss of GAR-2 ameliorated <italic>smn-1(rt248)</italic> aldicarb response. <italic>smn-1(+);gar-2(ok520)</italic> animals were hypersensitive to aldicarb. Time course for paralysis on 1 mM aldicarb in <italic>smn-1(+)</italic>, <italic>smn-1(rt248), smn-1(rt248);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic> early larval stage L4 animals. Log-rank test. (<bold>c</bold>) Loss of GAR-2 did not rescue <italic>smn-1(ok355)</italic> APT-4 (AP2 α-adaptin) defects. Loss of GAR-2 in the <italic>smn-1(+)</italic> background resulted in decreased APT-4 puncta width and intensity. Percent change from <italic>smn-1(+)</italic> control for APT-4 in the dorsal cord of <italic>smn-1(ok355), smn-1(ok355);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic> animals for ‘punctaanalyzer’ parameters: average puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to <italic>smn-1(+)</italic> control. Mann-Whitney <italic>U</italic>-test, two-tailed. GAR-2 loss did not rescue APT-4 puncta width (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);gar-2(ok520) p=</italic>0.12; <italic>smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=</italic>0.48), did not rescue APT-4 puncta intensity (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);gar-2(ok520) p=</italic>0.08; <italic>smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=</italic>0.54) and did not rescue APT-4 puncta linear density (<italic>smn-1(+)</italic> control <italic>versus smn-1(ok355);gar-2(ok520) p=</italic>0.66; <italic>smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=</italic>0.07). (<bold>d</bold>) Loss of GAR-2 ameliorated <italic>smn-1(rt248)</italic> SNB-1 (synaptobrevin) defects. Percent change from <italic>smn-1(+)</italic> control for SNB-1 in the dorsal nerve cord of <italic>smn-1(rt248),</italic> and <italic>smn-1(rt248);gar-2(ok520)</italic> animals for all ‘punctaanalyzer’ parameters: average puncta width (μm), total intensity (AU), and linear density (number/μm). <italic>smn-1(+);gar-2(ok520)</italic> percent change was collected alongside this data and is shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>. Asterisks denote significance compared to <italic>smn-1(+)</italic> control; shading indicates significant difference from <italic>smn-1(rt248);gar-2(ok520).</italic> Mann-Whitney <italic>U</italic>-test, two-tailed. Loss of GAR-2 rescued SNB-1 puncta width (<italic>smn-1(+)</italic> control <italic>versus smn-1(rt248);gar-2(ok520) p=</italic>0.83; <italic>smn-1(rt248) versus smn-1(rt248);gar-2(ok520) p=</italic>0.004), restored SNB-1 total puncta intensity (<italic>smn-1(+)</italic> control <italic>versus smn-1(rt248);gar-2(ok520) p=</italic>0.91; <italic>smn-1(rt248) versus smn-1(rt248);gar-2(ok520) p=</italic>0.004) and rescued SNB-1 puncta linear density (<italic>smn-1(+)</italic> control <italic>versus smn-1(rt248);gar-2(ok520) p=</italic>0.97; <italic>smn-1(rt248) versus smn-1(rt248);gar-2(ok520) p=</italic>0.002). (Martinez et al.) Representative images of SNB-1::RFP expressed in the dorsal nerve cord of cholinergic DA motor neurons for <italic>smn-1(+), smn-1(rt248), smn-1(rt248);gar-2(ok520),</italic> and <italic>smn-1(+);gar-2(ok520)</italic>. These images were taken as part of data collection. Scale bar, 5 μm. Figures E and H were taken from <xref ref-type="fig" rid="fig5">Figure 5</xref> since this data was collected alongside both <italic>ok355</italic> and <italic>rt248</italic> SNB-1::RFP data.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.031">http://dx.doi.org/10.7554/eLife.20752.031</ext-link></p><p><supplementary-material id="SD15-data"><object-id pub-id-type="doi">10.7554/eLife.20752.032</object-id><label>Figure 6—figure Supplement 1—source data 1.</label><caption><title>Raw Data for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title><p>Raw data and statistical analysis that correspond to APT-4::GFP localization analysis, RFP::SNB-1 localization analysis, aldicarb resistance and pumping assays in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.032">http://dx.doi.org/10.7554/eLife.20752.032</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig6-figsupp1-v1"/></fig></fig-group></p><p>Research in vertebrates has demonstrated m2R internalization normally occurs in response to chronic m2R stimulation, either by pharmacological agonist application or acetylcholinesterase inhibition (<xref ref-type="bibr" rid="bib9">Clancy et al., 2007</xref>). Since endocytosis is defective in animals lacking SMN-1, perturbed endocytosis, in combination with miRNA misregulation, could contribute to GAR-2 accumulation at the membrane leading to decreased SNB-1 in <italic>smn-1(ok355)</italic> motor neurons (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Loss of GAR-2 did not rescue <italic>smn-1(ok355)</italic> APT-4 puncta defects (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>), but decreased APT-4 puncta width and intensity in <italic>smn-1(+)</italic> control animals. As loss of GAR-2 did not restore APT-4 synaptic defects, we conclude that there are additional pathways affected by <italic>smn-1</italic> loss, beyond GAR-2 misregulation. Nevertheless, these results suggest that <italic>C. elegans</italic> GAR-2 levels are increased by <italic>smn-1</italic> loss, which might contribute to NMJ defects in <italic>smn-1(lf)</italic> animals.</p></sec><sec id="s2-7"><title>The GAR-2 mammalian ortholog, m2R, is increased in SMA mouse model motor neurons</title><p>The closest human ortholog of GAR-2 is the M2 muscarinic receptor (m2R), encoded by the <italic>CHRM2</italic> gene. GAR-2 and m2R are functionally conserved, as activation of these presynaptic receptors by acetylcholine in different species results in hyperpolarization and decreased NMJ acetylcholine release across species (<xref ref-type="bibr" rid="bib18">Dittman and Kaplan, 2008</xref>; <xref ref-type="bibr" rid="bib20">Dudel, 2007</xref>; <xref ref-type="bibr" rid="bib67">Parnas et al., 2005</xref>; <xref ref-type="bibr" rid="bib79">Slutsky et al., 2003</xref>). Previous research suggests decreased SMN function across species might impact miRNA activity across species, which could increase m2R levels consistent with our work in <italic>C. elegans.</italic> The <italic>CHRM2</italic> mRNA is a predicted target of miR-128 in mice and humans (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) (<xref ref-type="bibr" rid="bib41">Jan et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Lewis et al., 2005</xref>; <xref ref-type="bibr" rid="bib66">Paraskevopoulou et al., 2013</xref>). Based on results from <italic>C. elegans</italic>, we predicted that vertebrate SMN loss might disrupt miR-128 activity, also leading to increased m2R. m2R protein levels were examined in MNs isolated from E13.5 SMA mice (<italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup>). A ~50% increase in m2R levels was observed, compared to wild type control MNs (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>). miR-128 levels in SMA mouse MNs were decreased compared to wild type (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Combined, these results suggest that diminished SMN protein causes decreased levels of mature miR-128, thus disinhibiting m2R expression in MNs across species.<fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.20752.033</object-id><label>Figure 7.</label><caption><title>Increased m2R muscarinic receptor levels in SMA mouse model MNs contribute to axon outgrowth defects.</title><p>(<bold>a</bold>) Alignment of predicted miR-2 or miR-128 binding sites for <italic>C. elegans,</italic> mouse and human <italic>gar-2</italic> or <italic>CHRM2</italic> 3’UTRs. <italic>CHRM2</italic> encodes the mR2 muscarinic receptor (<xref ref-type="bibr" rid="bib66">Paraskevopoulou et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Reczko et al., 2012</xref>). Predicted nucleotide pairing shown by vertical lines. Red text indicates predicted miRNA seed region. A black line indicates potential seed region conservation. (<bold>b</bold>) Representative image for two E13.5 wild type and two <italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup> DIV10 spinal MN immunoblots probed for m2R and control β-Actin. (<bold>c</bold>) Quantification of immunoblot, <italic>t</italic>-test, two-tailed, p<italic>=</italic>0.017 (n = 14 for WT and n = 13 for SMA). (<bold>d</bold>) Quantification of miR-128 levels in DIV10 spinal MNs from E13.5 wild type and <italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup> animals. <italic>t</italic>-test, two-tailed (n = 24 from 12 mice for WT; n = 20 from 10 mice for SMA). (<bold>e</bold>) Longest axon length for E13.5 wild type and <italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup> DIV5 spinal MNs treated with 0 nm, 50 nm, and 500 nm methoctramine. <italic>t-</italic>test, two-tailed. (n = 103 for WT 0 nM, n = 131 for WT 50 nM, n = 98 for WT 500 nM, n = 102 for SMA 0 nM, n = 67 for SMA 50 nM and n = 53 for SMA 500 nM) (<bold>f</bold>) Proposed model: SMN acts via MEL-46 to influence microRNAs that play important roles in NMJ function and MN survival. SMN loss affects other pathways as well. <italic>C. elegans</italic> genes shown on left side; human genes on right side.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.033">http://dx.doi.org/10.7554/eLife.20752.033</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig7-v1"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.20752.034</object-id><label>Figure 7—figure supplement 1.</label><caption><title>m2R inhibition by methoctramine increases axon length in SMA mouse model MNs.</title><p>(<bold>a</bold>) Total axon length for E13.5 wild type and <italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup> DIV5 spinal MNs treated with 0 nm, 50 nm, and 500 nm methoctramine. ‘Total axon length’ is a measurement of all axon branches. <italic>t-</italic>test, two-tailed. n = 103 for WT 0 nM, n = 131 for WT 50 nM, n = 98 for WT 500 nM, n = 102 for SMA 0 nM, n = 67 for SMA 50 nM and n = 53 for SMA 500 nM. Neurons are from at least three biological samples.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.034">http://dx.doi.org/10.7554/eLife.20752.034</ext-link></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-20752-fig7-figsupp1-v1"/></fig></fig-group></p></sec><sec id="s2-8"><title>Inhibition of m2R by methoctramine rescued axon outgrowth defects in SMA mouse model MNs</title><p>Decreased SMN levels results in axon outgrowth defects in MNs derived from a SMA mouse model (<xref ref-type="bibr" rid="bib73">Rossoll et al., 2003</xref>) and increased m2R might contribute to this functional defect. To test this, we examined the impact of m2R pharmacological inhibition on axon length for DIV5 MNs from E13.5 wild type (FVB) and SMA mice (<italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup>) (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Wild type and SMA MNs were cultured in the presence of 50 nm or 500 nm methoctramine, an m2R antagonist. In wild type MNs, methoctramine decreased mean longest axon length. Conversely, methoctramine treatment in SMA MNs increased both mean longest axon length and total axon length (<xref ref-type="fig" rid="fig7">Figure 7E</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). We conclude that m2R inhibition rescues MN axon outgrowth defects in a SMA mouse model, consistent with a deleterious impact of increased m2R activity in SMA model MNs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our understanding of the mechanisms by which SMN loss influences MN function and survival remains incomplete. Many pathways are perturbed by SMN loss, including spliceosome assembly, pre-mRNA splicing, mRNA transport, endocytosis, and axon growth (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib23">Fallini et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Hosseinibarkooie et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">McWhorter et al., 2003</xref>; <xref ref-type="bibr" rid="bib58">Meister et al., 2001</xref>; <xref ref-type="bibr" rid="bib69">Pellizzoni et al., 2002</xref>). As the human <italic>CHRM2</italic> locus lacks introns (<xref ref-type="bibr" rid="bib31">Gosso et al., 2007</xref>), spliceosomal defects caused by SMN1 loss of function are unlikely to directly affect mature <italic>CHRM2</italic> mRNA levels, although indirect effects are possible. Based on our results, the simplest model explaining why SMN loss alters m2R levels is one in which decreased SMN levels impact Gemin3 function, thus perturbing miRNA pathways, including miR-128 suppression of m2R translation. As m2R receptors inhibit cholinergic MN synaptic release (<xref ref-type="bibr" rid="bib79">Slutsky et al., 2003</xref>), m2R up-regulation may contribute to MN defects in early stages of SMA pathogenesis, in parallel to perturbation of other pathways affected by SMN loss (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p><sec id="s3-1"><title>SMN-1 loss impacts miRNA activity in <italic>C. elegans</italic> potentially via MEL-46/Gemin3</title><p>The most direct molecular connection between SMN and the miRNA pathway is Gemin3. Results presented here indicate that decreases in SMN-1(SMN) or MEL-46(Gemin3) result in similar neuromuscular defects as well as decreased miR-2 levels in neurons. This analysis further suggests that decreases in <italic>C. elegans</italic> SMN-1 result in increased GAR-2 (m2R) through miR-2 misregulation and that increasing MEL-46 (Gemin3) reduces GAR-2 protein levels in <italic>smn-1(ok355)</italic> animals <italic>via</italic> modulation of miR-2. Several lines of evidence support this conclusion, including miR-2 GFP reporter expression results, NMJ aldicarb sensitivity, synaptic protein localization changes, and qPCR measurements of mature miR-2 and <italic>gar-2</italic> mRNA levels (<xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig5">5</xref>).</p><p>There is a paucity of research addressing the functional importance of Gemin3, in either the Gemin or the RISC complexes. Biochemical and co-localization studies support a role for Gemin3 in spliceosome assembly, mRNA transport, and miRNA function (<xref ref-type="bibr" rid="bib8">Charroux et al., 1999</xref>; <xref ref-type="bibr" rid="bib19">Dostie et al., 2003</xref>; <xref ref-type="bibr" rid="bib24">Feng et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Mourelatos et al., 2002</xref>; <xref ref-type="bibr" rid="bib98">Zhang et al., 2006</xref>). It is possible that decreased and/or mislocalized Gemin3 impairs RISC function, leading to the diminished miR-2 activity and levels reported in <xref ref-type="fig" rid="fig5">Figure 5</xref>. However, since Gemin3 likely functions in numerous pathways, it may influence miR-2 through other, more indirect pathways. In <italic>Drosophila</italic>, Gemin3 is necessary for motor function, but the molecular mechanisms underlying this defect are unclear (<xref ref-type="bibr" rid="bib6">Cauchi et al., 2008</xref>). Results presented here in <italic>C. elegans</italic> further support a requirement for Gemin3 in motor function and additionally, show that Gemin3 is capable of modifying miRNA levels and activity.</p></sec><sec id="s3-2"><title>SMN depletion results in miRNA misregulation across species</title><p>miR-2 belongs to the invertebrate K box family (motif: CUGUGAUA) of miRNAs (<xref ref-type="bibr" rid="bib39">Ibáñez-Ventoso et al., 2008</xref>). It was suggested previously that miR-2 does not have well-conserved mammalian orthologs (<xref ref-type="bibr" rid="bib55">Marco et al., 2012</xref>), but another study suggested that human miR-128 is a member of this miRNA family (<xref ref-type="bibr" rid="bib39">Ibáñez-Ventoso et al., 2008</xref>). These two bioinformatics studies differ in their definition of the miRNA binding site, also known as the seed region. Our alignment of miR-2/miR-128 miRNAs and <italic>gar-2/CHRM2</italic> mRNAs suggests that the CUGUG seed region may be a conserved motif for miRNA binding (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Both miR-2 and miR-128 are enriched in the nervous system and share conserved mRNA targets (<xref ref-type="bibr" rid="bib55">Marco et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Martinez et al., 2008</xref>). More studies will be needed to confirm that miR-2 and miR-128 are orthologs. Regardless, the results presented here, in conjunction with previous research, suggest that overall miRNA misregulation contributes to neuronal defects when SMN levels decrease (<xref ref-type="bibr" rid="bib33">Haramati et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Kye et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Valsecchi et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Wang et al., 2014</xref>; <xref ref-type="bibr" rid="bib92">Wertz et al., 2016</xref>).</p><p>Altered function of miR-2/miR-128 or GAR-2/m2R is not sufficient to explain all of the dysfunction observed in models of SMN deficiency. In <italic>C. elegans,</italic> miR-2 loss does not cause overt defects and GAR-2 loss does not restore viability, fecundity, or normal development to animals lacking SMN-1 or MEL-46. This suggests miR-2 loss does not contribute to defects outside the NMJ caused by SMN-1 loss. And, at the NMJ, synaptic protein perturbations are more severe in animals with diminished SMN-1 or MEL-46, compared to those lacking either miR-2 or GAR-2, which is consistent with a broader range of defects caused by decreased SMN-1 levels. In mice, complete miR-128 knock-out results in decreased motor activity and premature death (<xref ref-type="bibr" rid="bib82">Tan et al., 2013</xref>), but it is currently unknown how miR-128 loss might specifically impact cholinergic MN function.</p></sec><sec id="s3-3"><title>M2 receptor expression is increased in SMA model MNs</title><p>We found that m2R levels were increased 50% overall in SMN-deficient mouse MNs compared to wild type by Western blot analysis (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>). In <italic>C. elegans</italic>, relative GAR-2 translation was increased by only 5% globally when SMN-1 levels dropped, based on GFP reporter expression in cholinergic neurons (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). These two assays are not directly comparable, since the <italic>C. elegans</italic> experiment only investigated the contribution of miR-2 perturbation in regards to increased GAR-2 translation. Certainly, additional pathways are affected by SMN loss, beyond miRNAs, contributing to the greatly increased m2R levels in SMN-deficient MNs. These pathways may include mRNA transport metabolism, endocytosis, as well as spliceosome and ribonucleoprotein assembly (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib23">Fallini et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Hosseinibarkooie et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Pellizzoni et al., 2002</xref>; <xref ref-type="bibr" rid="bib96">Yong et al., 2002</xref>). Extensive analysis would be required to understand how defects in these pathways contribute to increased m2R in SMN-deficient MNs.</p></sec><sec id="s3-4"><title>Could increased M2 muscarinic receptor expression contribute to α-MN defects in SMA patients?</title><p>m2R is expressed in α-MNs, with little to no expression in smaller gamma MNs (<xref ref-type="bibr" rid="bib91">Welton et al., 1999</xref>). This expression profile correlates with the pattern of neurodegeneration in an SMA mouse model: selective loss of α-MNs, while gamma MNs remain unaffected (<xref ref-type="bibr" rid="bib70">Powis and Gillingwater, 2016</xref>). Within α-MNs, m2R is distributed along the membrane and concentrates at postsynaptic connections with C-boutons (<xref ref-type="bibr" rid="bib13">Deardorff et al., 2014</xref>). α-MNs in SMNΔ7 mice have increased C-bouton sites (<xref ref-type="bibr" rid="bib83">Tarabal et al., 2014</xref>), which could be an additional cause or consequence of increased m2R levels in α-MNs. Taken together, this evidence suggests that increased m2R is consistent with multiple features of SMA pathology. We also consider three additional previously defined m2R pathways as possible contributors to MN functional defects in SMN-deficient α-MNs: GIRK channels, Ca<sup>2+</sup> channels, and SK channels.</p><p>Classically, m2R receptor activation leads to GIRK-channel-dependent efflux of K<sup>+</sup> cations, resulting in neuronal hyperpolarization and decreased SV release (<xref ref-type="bibr" rid="bib81">Sun et al., 2013</xref>). Therefore, increased m2R levels are consistent with the synaptic defects observed in SMA models across species (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Kong et al., 2009</xref>). m2R activation of GIRK channels is conserved in <italic>C. elegans</italic> (<xref ref-type="bibr" rid="bib49">Lee et al., 2000</xref>), suggesting GAR-2 loss may rescue NMJ defects in animals lacking SMN-1 by reducing GIRK channel activation. Interestingly, sustained GIRK activation has been previously linked to neurodegeneration (<xref ref-type="bibr" rid="bib11">Coulson et al., 2008</xref>).</p><p>m2R inhibits N-type Ca<sup>2+</sup> (Ca<sub>v</sub>2.2) and P/Q-type Ca<sup>2+</sup> (Ca<sub>v</sub>2.1) channels resulting in decreased SV release at the NMJ (<xref ref-type="bibr" rid="bib79">Slutsky et al., 2003</xref>; <xref ref-type="bibr" rid="bib95">Yan and Surmeier, 1996</xref>). And, Ca<sub>v</sub>2.1-deficient mice exhibit NMJ degeneration and decreased active zone proteins (<xref ref-type="bibr" rid="bib26">Fox et al., 2007</xref>; <xref ref-type="bibr" rid="bib64">Nishimune et al., 2004</xref>). Additionally, in a mouse model of SMA, distal axons and growth cones had reduced Ca<sup>2+</sup> transients resulting from defective Ca<sub>v</sub>2.2 excitability and accumulation (<xref ref-type="bibr" rid="bib40">Jablonka et al., 2007</xref>). Increased m2R is consistent with decreased Ca<sup>2+</sup> channel activity observed in SMN-deficient animals. Moreover, Ca<sub>v</sub>2.2 channels activate SK channels in α-MNs, suggesting increased m2R may lead to decreased SK channel currents (<xref ref-type="bibr" rid="bib29">Goldberg and Wilson, 2005</xref>). The drug riluzole, which ameliorated motor defects in <italic>smn-1(ok355)</italic> animals, may act <italic>via</italic> SK channels (<xref ref-type="bibr" rid="bib16">Dimitriadi et al., 2013</xref>). Increased m2R levels may result in excessive inhibition of SK channels, contributing to defective synaptic transmission in SMA models across species; this connection may offer additional mechanistic insight into the ameliorative effects of riluzole.</p><p>Previous reports suggest that decreases in Ca<sup>2+</sup> transients hinder axon outgrowth (<xref ref-type="bibr" rid="bib36">Hutchins and Kalil, 2008</xref>). SMN loss also decreases these currents (<xref ref-type="bibr" rid="bib40">Jablonka et al., 2007</xref>), consistent with defective axon outgrowth in SMN-deficient cultured neurons. Here, we show that inhibition of m2R by methoctramine ameliorates axon outgrowth defects in SMA mouse model MNs. As we find m2Rs are overexpressed in SMA MNs, methoctramine rescue of axon outgrowth may be the result of restored Ca<sup>2+</sup> channel function. Taken together, these data suggest that increased m2R expression contributes to axon outgrowth defects in SMA MNs and that m2R inhibition promotes axon outgrowth in SMA MNs.</p><p>We connect SMN functionally and mechanistically to the miRNA pathway. As an exemplar of this connection in two species, we demonstrate that decreased SMN levels lead to downregulation of specific miRNAs and consequent increased expression of M2 muscarinic receptors. Increased m2R activity is deleterious and consistent with a subset of the NMJ defects seen in SMA models, across species. We suggest future studies might address the possible benefits of m2R inhibition in SMA models, as a combinatorial approach with other therapies.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title><italic>C. elegans</italic> strains, constructs and transgenes</title><p>Strains listed in <xref ref-type="supplementary-material" rid="SD17-data">Supplementary file 2A</xref> were maintained under standard conditions at 25°C (<xref ref-type="bibr" rid="bib3">Brenner, 1974</xref>); we provide complete genotypes with unique strain identifiers, consistent with the rigorous standards of the <italic>C. elegans</italic> community. Abbreviated names are sometimes used for arrays, integrated lines or alleles in <xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig5">5</xref>; additional information about abbreviations can be found in <xref ref-type="supplementary-material" rid="SD17-data">Supplementary file 2C</xref>. For experiments with <italic>smn-1(ok355)</italic> and <italic>smn-1(rt248),</italic> animals assayed were first generation progeny of hermaphrodites heterozygous for the <italic>hT2</italic> balancer. To maintain a common genetic background, control <italic>smn-1(+)</italic> animals were also derived from +/<italic>hT2</italic> parents. Similarly, for APT-4::GFP synaptic localization (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>) and aldicarb response studies (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), <italic>mel-46(tm1739)</italic> animals were first generation progeny of parents heterozygous for the <italic>nT1</italic> balancer. Control <italic>mel-46(+)</italic> animals were derived from +/<italic>nT1</italic> animals. For all other assays involving <italic>mel-46(tm1739)</italic>, animals were first generation progeny of parents carrying the <italic>ytEx211[mel-46(+)]</italic> rescue array; animals tested did not carry the array unless specified. For these experiments, N2 animals served as wild type controls. We attempted to generate <italic>smn-1(ok355);mel-46(tm1739)</italic> double mutant animals, but generation of heterozygous double mutant animals was not possible, using either balancer chromosomes or the <italic>ytEx211[mel-46(+)]</italic> rescue array.</p><p>The pHA#756 (<italic>unc-17p::mir-2::unc-54</italic> 3’UTR) plasmid was generated by excising a 867 bp fragment from pHA#755 (<italic>aex-3p::mir-2::unc-54</italic> 3’UTR) using NheI and SpeI. This fragment, containing the genomic <italic>mir-2</italic> pre-miRNA sequence along with <italic>unc-54</italic> 3’UTR sequence, was subcloned into pPD95.77 (pPD95.77 was a gift from Andrew Fire; Addgene, Cambridge, Massachusetts plasmid 1495) between NheI and SpeI sites, resulting in removal of the GFP sequence. Additionally, a 4466 bp fragment corresponding to the <italic>unc-17</italic> promoter was inserted between pPD95.77 SphI and AscI sites. Information for all amplification primers can be found in <xref ref-type="supplementary-material" rid="SD17-data">Supplementary file 2B</xref>. pHA#757 (<italic>unc-17p::GFP::unc-54</italic> 3’UTR) was generated by inserting the <italic>unc-17</italic> promoter fragment between pPD95.77 SphI and AscI sites, without altering the GFP sequence. Plasmid pHA#758 (NLS::GFP::<italic>gar-2</italic> 3’UTRwt) contains a 269 bp fragment corresponding to the <italic>gar-2</italic> 3’UTR that was subcloned into pPD95.67 (pPD95.67 was a gift from Andrew Fire; Addgene plasmid 1490) as a EcoRI and SpeI product. pHA#759 (<italic>unc-17p::NLS::GFP::gar-2</italic> 3’UTRwt) was generated by excising a 1286 bp fragment containing the NLS::GFP sequence and <italic>gar-2</italic> 3’UTR from pHA#758 using MscI and SpeI and ligating this fragment into pHA#756, thus removing the genomic <italic>mir-2</italic> pre-miRNA and <italic>unc-54</italic> 3’UTR sequences. pHA#760 was generated by ligating the <italic>gar-2</italic> 3’UTR fragment into pBluescript KS+ (Stratagene, La Jolla, California) using EcoRI and SpeI. To construct pHA#761, the last 85 bp of the <italic>gar-2</italic> 3’UTR were removed from pHA#760 using NcoI and SpeI. This fragment was replaced with an identical 85 bp sequence, but with 19 bp scrambled at the predicted miR-2 binding site sequence (<italic>gar-2</italic> 3’UTRscr). Primers were annealed to produce this 85 bp sequence (<xref ref-type="supplementary-material" rid="SD17-data">Supplementary file 2C</xref>). Plasmid pHA#762 (NLS::GFP::<italic>gar-2</italic> 3’UTRscr) was generated by subcloning the 269 bp <italic>gar-2</italic> 3’UTRscr fragment from pHA#761 into pPD95.67 with EcoRI and SpeI. pHA#763 (<italic>unc-17p::NLS::GFP::gar-2</italic> 3’UTRscr) was produced by subcloning the 1286 bp fragment containing NLS::GFP and <italic>gar-2</italic> 3’UTRscr sequences from pHA#762 into pHA#756 using MscI and SpeI, while removing the genomic <italic>mir-2</italic> pre-miRNA and <italic>unc-54</italic> 3’UTR sequences. pHA#790 (<italic>unc-122p::mel-46::unc-54</italic> 3’UTR) was created by amplifying the MEL-46 coding region from the pRM8 plasmid (<xref ref-type="bibr" rid="bib61">Minasaki et al., 2009</xref>) and inserting this fragment into the pHA#729 EcoRI site (<xref ref-type="bibr" rid="bib17">Dimitriadi et al., 2016</xref>). Using SphI and MscI restriction enzymes, the <italic>unc-122</italic> promoter was then excised and replaced with the 4466 bp <italic>unc-17</italic> promoter fragment excised from pHA#763 with the same enzymes, thus generating pHA#791 (<italic>unc-17::mel-46::unc-54</italic> 3’UTR). To create pHA#792 (<italic>unc-17p::mel-46</italic>::GFP::<italic>unc-54</italic> 3’UTR), a 906 bp GFP sequence was amplified from pHA#763 and subcloned by Gibson assembly into pHA#791 just before the MEL-46 stop codon (TGA). The small guide RNA (sgRNA) plasmids targeting the <italic>smn-1</italic> gene (pHA#764 and pHA#765) and the sgRNA plasmid targeting the <italic>gar-2</italic> 3’UTR (pHA#793) for CRISPR/Cas9-mediated genome editing were produced by amplification of <italic>PU6::klp-12</italic> (<xref ref-type="bibr" rid="bib27">Friedland et al., 2013</xref>). Plasmid pHA#766 contains a GFP insertion template and self-excising cassette flanked by <italic>smn-1</italic> arms of homology that were subcloned by Gibson assembly into pDD282 following a protocol from (<xref ref-type="bibr" rid="bib14">Dickinson et al., 2015</xref>).</p><p>Integrated arrays <italic>rtIs64</italic> and <italic>rtIs65 [unc-17p::mel-46</italic>::GFP::<italic>unc-54</italic> 3’UTR] were created by UV irradiation of <italic>rtEx871</italic>, which were generated by standard injection of pHA#792 at 50 ng/μl, alongside 5 ng/μl <italic>myo-3p::</italic>mCherry (pCFJ104 - <italic>myo-3p::</italic>mCherry::<italic>unc-54utr</italic> was a gift from Erik Jorgensen (<xref ref-type="bibr" rid="bib28">Frøkjaer-Jensen et al., 2008</xref>), and 75 ng/μl pBluescript KS+. To generate <italic>rtEx855[</italic>pRM8(<italic>mel-46(</italic>+); <italic>myo-2p</italic>::RFP], wild type animals were injected with 133 ng/μl PRM8 plasmid (<xref ref-type="bibr" rid="bib61">Minasaki et al., 2009</xref>), 5 ng/μl <italic>myo-3p::</italic>mCherry; Addgene plasmid 19328) and 75 ng/μl pBluescript KS+. Animals injected with rtEx855[pRM8(<italic>mel-46(+); myo-3p-</italic>RFP)] were crossed into a <italic>mel-46(tm1739)</italic> background to assure rescue of viability before further experiments were undertaken. Notably, expression of either <italic>rtEx855</italic> or <italic>ytEx211</italic> in <italic>smn-1(lf)</italic> animals did not rescue lethality or adult survival, further emphasizing a privileged relationship between SMN-1 and MEL-46 in cholinergic NMJ signaling. Lines for <italic>rtEx853[unc-17p::mir-2; myo-2p::mCherry]</italic> and <italic>rtEx854[unc-17p::GFP; myo-2p::mCherry]</italic> were produced by injecting <italic>mir-2(gk259)</italic> animals with pHA#756 or pHA#757, respectively, a<italic>t 40</italic> ng/μl alongside 2.5 ng/μl <italic>myo-2p::</italic>mCherry (pCFJ90 - <italic>myo-2p::</italic>mCherry<italic>::unc-54utr</italic> was a gift from Erik Jorgensen (<xref ref-type="bibr" rid="bib28">Frøkjaer-Jensen et al., 2008</xref>); Addgene plasmid 19327) and 77.5 ng/μl pBluescript KS+. <italic>rtIs56[unc-17p::GFP::gar-2 3’UTRwt; myo-2p::mCherry]</italic> was integrated by UV irradiation into the genome and is derived from extrachromosomal array <italic>rtEx856</italic>, containing pHA#759, which was injected into wild type animals at 20 ng/μl with 2.5 ng/μl <italic>myo-2p::mCherry</italic> and 77.5 ng/μl pBluescript KS+. Integrated arrays <italic>rtIs57</italic> and <italic>rtIs58 [unc-17p::GFP::gar-2 3’UTRscr; myo-2p::mCherry]</italic> are two separate lines generated by UV irradiation of extrachromosomal array <italic>rtEx857,</italic> containing pHA#763, which was injected into wild type animals at 20 ng/μl with 2.5 ng/μl <italic>myo-2p::mCherry</italic> and 77.5 ng/μl pBluescript KS+. <italic>gar-2(rt317)</italic> and <italic>gar-2(rt318)</italic> alleles were generated by injecting <italic>pha-1</italic>(<italic>e2123</italic>) animals with the pHA#793 sgRNA plasmid targeting the <italic>gar-2</italic> 3’UTR at 25 ng/μl with either 50 ng/μl of a mutant single-strand oligo DNA (ssODN) repair template (<italic>rt318)</italic> or a control ssODN repair template (<italic>rt317</italic>), alongside the injection cocktail as described in <xref ref-type="bibr" rid="bib90">Ward (2015)</xref>. Progeny from this injection were screened as described (<xref ref-type="bibr" rid="bib90">Ward, 2015</xref>). Information on ssODN template sequences can be found in <xref ref-type="supplementary-material" rid="SD17-data">Supplementary file 2C</xref>. To generate <italic>smn-1(rt280),</italic> which contains a GFP N-terminal insertion, wild type animals were injected with both pHA#764 and pHA#765 sgRNA plasmids targeting <italic>smn-1</italic> at 50 ng/μl alongside 20 ng/μl of the GFP template plasmid pHA#766 and the standard injection cocktail described in <xref ref-type="bibr" rid="bib14">Dickinson et al. (2015)</xref>. Progeny from this injection were screened as described (<xref ref-type="bibr" rid="bib14">Dickinson et al., 2015</xref>). Consistent with Miguel-Aliaga et al., we noticed that the tagged-SMN protein was expressed in all blastomeres throughout embryonic development with redistribution from the nucleus to the cytoplasm during mitotic stages (data not shown). The presence of GFP::SMN during such early stages indicates that GFP::SMN is maternally transmitted during germline development (<xref ref-type="bibr" rid="bib60">Miguel-Aliaga et al., 1999</xref>).</p></sec><sec id="s4-2"><title>RNAi studies</title><p>RNAi studies involved animals from an RNAi-enhanced background (KP3948) (<xref ref-type="bibr" rid="bib44">Kennedy et al., 2004</xref>), neuron-specific RNAi-sensitized background (TU3401) (<xref ref-type="bibr" rid="bib5">Calixto et al., 2010</xref>), cholinergic neuron-specific RNAi-sensitized background (XE1581), or GABA neuron-specific RNAi-sensitized background (XE1375) (<xref ref-type="bibr" rid="bib25">Firnhaber and Hammarlund, 2013</xref>). Aldicarb response, pumping rates, and RNA quantification were evaluated in animals that had been reared for at least two generations on HT115 bacteria containing control vector L4440, C41G7.1/<italic>smn-1(RNAi),</italic> C26C6.2/<italic>goa-1(RNAi)</italic>, T06A10.1/<italic>mel-46(RNAi),</italic> or Y37D8A.23/<italic>unc-25(RNAi)</italic> (<xref ref-type="bibr" rid="bib42">Kamath and Ahringer, 2003</xref>). Primer sequences used to generate the PCR products specific to each gene of interest can be found on the Kim Lab Stanford University website (<ext-link ext-link-type="uri" xlink:href="http://cmgm.stanford.edu/~kimlab/primers.12-22-99.html">http://cmgm.stanford.edu/~kimlab/primers.12-22-99.html</ext-link>).</p></sec><sec id="s4-3"><title><italic>C. elegans</italic> behavioral assays</title><p><italic>Aldicarb resistance assay:</italic> 1 mM aldicarb assays were completed in at least three independent trials blinded to genotype (n ≥ 30 animals/genotype) as described in previous work (<xref ref-type="bibr" rid="bib54">Mahoney et al., 2006</xref>; <xref ref-type="bibr" rid="bib74">Sato et al., 2009</xref>). Paralysis induced by aldicarb was scored as inability to move or pump in response to prodding with a platinum wire. Experiments involving <italic>smn-1(ok355), smn-1(rt248)</italic> or <italic>mel-46(tm1739)</italic> animals were completed at the early L4 stage. All other aldicarb experiments were done with young adult animals. <italic>Pharyngeal pumping:</italic> Assays were performed blinded to genotype as previously described (<xref ref-type="bibr" rid="bib15">Dimitriadi et al., 2010</xref>). Pumping events were scored as grinder movement in any axis. Average pumping rates (± Standard Error of the Mean (SEM)) were pooled from at least two independent trials (n &gt; 20 animals/genotype). Experiments involving <italic>smn-1(ok355), smn-1(rt248)</italic> or <italic>mel-46(tm1739)</italic> animals were completed at day three post-hatching (animals were kept at 25<bold>°</bold>C for two days and then 20<bold>°</bold>C for one day). Pumping experiments involving all other genotypes were done with young adult animals.</p></sec><sec id="s4-4"><title><italic>C. elegans</italic> light level microscopy</title><p>Animals were mounted on 2% agar pads and immobilized using 30 mg/mL BDM (Sigma) in M9 buffer. <italic>Dorsal cord protein localization:</italic> Images were obtained as Z-stacks of the dorsal cord above the posterior gonad reflex (100x objective, Zeiss (Jena, Germany) AxioImager ApoTome and Axiovision software v4.8). For MEL-46::GFP analysis, a set area was defined for each image along the dorsal cord (25 µm x 5 µm). Using ImageJ (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link>), a uniform threshold was used to eliminate background. The number (density), mean fluorescence (intensity) and area (size) for MEL-46::GFP granular structures were calculated using the ImageJ ‘particle analyzer’ program. For synaptic protein localization, mean puncta width (meanfixedwidth), intensity (meanfixedvolume) and linear density (fixedwidthlineardensity) were quantified with an in-house developed program called ‘Punctaanalyser’ using MatLab software (v6.5; Mathworks, Inc., Natick, MA, USA; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001622">SCR_001622</ext-link>) (<xref ref-type="bibr" rid="bib45">Kim et al., 2008</xref>). At least three independent trials (n &gt; 17 animals/genotype) were performed. For data sets involving <italic>smn-1(ok355), smn-1(rt248),</italic> or <italic>mel-46(tm1739)</italic> animals, all genotypes were examined at the early L4 stage, while other data sets were collected with young adult stage animals. <italic>GFP Fluorescence Quantification:</italic> GFP images of L4 animals were acquired (10x objective, Zeiss V20 stereoscope and Axiovision software v4.8). Mean GFP fluorescence was quantified using ImageJ (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link>). A threshold was set to eliminate background fluorescence. For each data set, thresholds were kept constant. Average fluorescence values (±SEM) were combined from at least three independent trials for n &gt; 25 animals/genotype; however certain backgrounds containing <italic>rtEx855[mel-46(+)]</italic> had a lower n (reported in legends) as these animals went sterile and/or did not throw many progeny carrying the <italic>mel-46</italic> array. Ratios in <xref ref-type="fig" rid="fig4">Figure 4H</xref> and <xref ref-type="fig" rid="fig5">Figure 5A</xref> were calculated as average mean fluorescence for each genotype in the <italic>rtIs56</italic> background and divided by their respective average mean fluorescence in the control <italic>rtIs57</italic> background. Ratio SEM was calculated by summing the SEM for each population (see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). All representative images shown were analyzed as part of data collection.</p></sec><sec id="s4-5"><title><italic>C. elegans</italic> total RNA isolation, cDNA synthesis and qPCR</title><p>For each RNA sample, animals were synchronized by collecting eggs for 6 hr from gravid adults on large seeded NGM plates. After two days at 25°C, young adult progeny were washed off, rinsed and flash frozen. Total RNA was extracted after a 15 min Trizol (Thermo Fisher, Waltham, Massachusetts) incubation. 1 ng total RNA was used for reverse transcription with either the miScript II RT kit (Qiagen #218160) for miRNA or the SuperScript III First-Strand Synthesis Supermix kit (Invitrogen #11752050) for mRNA. Methodology followed manufacturer’s instructions. miRNA levels were determined in a 10 µl reaction using miScript SYBR Green PCR kit (#218073, Qiagen, Venlo, Netherlands) and 300 nM of mature miR-2 primer/probe. miR-60 was used to normalize miR-2 expression as it is not expressed in the nervous system where SMN-1 or MEL-46 were knocked-down. Forward primer sequences for miR-2 and miR-60 were, respectively: 5’-TATCACAGCCAGCTTTGATGTGC-3’ and 5’-TATTTATGCACATTTTCTAGTTCA-3’. A universal reverse probe was provided by Qiagen. Primer sequences for <italic>act-1</italic>: 5’-acgccaacactgttctttcc-3’ and 5’-gatgatcttgatcttcatggttga-3’ (<xref ref-type="bibr" rid="bib53">Ly et al., 2015</xref>). Primer sequences for 18S rRNA: 5’-TTGCTGCGGTTAAAAAGCTC’3’ and 5’-CCAACCTCAAACCAGCAAAT-3’ (<xref ref-type="bibr" rid="bib22">Essers et al., 2015</xref>). The stability of miR-60, 18S rRNA, and <italic>act-1</italic> housekeeping RNAs were evaluated using the ‘model-based approach to estimation of expression variation’ (<xref ref-type="bibr" rid="bib2">Andersen et al., 2004</xref>). mRNA levels were determined in a 10 µl reaction using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific # 4368706), and 300 nM of each primer. PGK-1 was used to normalize <italic>gar-2</italic> expression, as the mammalian orthologue has been used previously as a housekeeping gene for experiments involving SMN (<xref ref-type="bibr" rid="bib1">Abera et al., 2016</xref>; <xref ref-type="bibr" rid="bib77">Simard et al., 2007</xref>). Primer sequences for <italic>gar-2</italic>: 5’-CCTGAACTCTCATTGCCCTTTATTGATGC-3’ and 5’-CTAGCAGTCCCTTGCATTGAAAC-3’. Primer sequences for <italic>pgk-1</italic>: 5’-GGCCCTCGACAACCCAGCTCGTC-3’ and 5’-CGGCGGAGGAATGGCCTATACC-3. All reactions were performed in triplicate. Melting curve analysis and electrophoresis in agarose gel of every PCR product was conducted after each qRT-PCR to control amplification specificity. Gene expression level was calculated as the fold change of relative DNA amount of a target gene in a target sample and a reference sample normalized to a reference gene using the comparative ΔΔCT method as previously described (<xref ref-type="bibr" rid="bib47">Kurrasch et al., 2004</xref>).</p></sec><sec id="s4-6"><title>Embryonic spinal MN culture, miR-128a quantification and Western blot</title><p>E13.5 mouse MNs were isolated from WT (FVB/NJ; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:001800">IMSR_JAX:001800</ext-link>) and SMA mice (FVB, <italic>Smn</italic><sup>-/-</sup>;<italic>SMN2</italic><sup>tg/0</sup>; generated by crossing lines RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:005058">IMSR_JAX:005058</ext-link> and RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:005024">IMSR_JAX:005024</ext-link>) (<xref ref-type="bibr" rid="bib72">Riessland et al., 2010</xref>) as described (<xref ref-type="bibr" rid="bib94">Wiese et al., 2001</xref>). Isolated mouse MNs were differentiated 10 days in NB/B27 media supplemented with growth factors to promote survival; brain derived neurotrophic factor (BDNF) 10 ng/ml, ciliary neurotrophic factor (CNTF) 10 ng/ml and glial-derived neurotrophic factor (GDNF) 50 ng/ml. Fifty percent of medium was replaced every three days. To reduce the amount of glia and fibroblasts in culture, 1 µM cytosine arabinoside (AraC) was added at day 3.</p><p>After 10 days in vitro culture, total RNA was extracted from MNs using the mirVana total RNA isolation kit (Thermo Scientific). Nanodrop was used to measure RNA amount. Using 100 ng of total RNA, miR-128 expression levels were determined by real time PCR with mature miR-128a primer/probe (TaqMan MicroRNA Assays, #4427975, Thermo Scientific). Actin-beta was used to normalize miR-128a expression. Primer sequences for actin-beta: 5'-agccatgtacgtagccatcc-3' and reverse 5'-ctctcagctgtggtggtgaa-3'. Methodology followed manufacturer’s instruction (<xref ref-type="bibr" rid="bib48">Kye et al., 2014</xref>).</p><p>Proteins were extracted from motor neurons, after 10 days in vitro culture, using RIPA buffer and protease inhibitor cocktail (<xref ref-type="bibr" rid="bib80">Smith et al., 2014</xref>). Expression of m2R and β-actin was measured using Western blot. Antibodies against m2R (ABCAM, ab109226; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10858602">AB_10858602</ext-link>; 1:1000) and β-actin (Santa Cruz, sc-47778; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_626632">AB_626632</ext-link>; 1:1000) were used to detect proteins. Methoctramine (Sigma, M105) was treated 48 hr from DIV3 to DIV5 in various concentrations. After 5 days of in vitro culture, neuronal morphology was visualized with Tau (Santa Cruz, A-10) staining. Axon length was analyzed with ImageJ (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link>).</p></sec><sec id="s4-7"><title>Statistical analysis</title><p>Log-rank test, two-tailed Mann-Whitney <italic>U</italic>-test, or <italic>t-</italic>test were used for <italic>C. elegans</italic> statistical analysis. The Mann Whitney <italic>U</italic>-test was chosen over <italic>t-</italic>test for experiments where homogeneity could not be assured (i.e. RNAi; extrachromosomal arrays; or potential maternal loading from a heterozygous parent). <italic>t</italic>-test was used to determine significance for spinal motor neuron Western blot quantification and qPCR quantification.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the Streit lab for providing the PRM8[<italic>mel-46(+)</italic>] construct. We also thank the Jorgensen, Fire and Ahringer labs for sharing numerous plasmids. The Kaplan lab provided strains containing synaptic protein localization markers. Additional strains were provided by the CGC, funded by the NIH Office of Research Infrastructure Programs (P40 OD010440). This work was supported by the SMA Foundation and NIH NINDS (NS066888) to ACH, as well as NIH pre-doctoral training grants (2T32MH020068-11 and 5T32MH020068-12) and a NIH NINDS Ruth L Kirschstein National Research Service Award (F31NS089201) to PJO. The Kye lab was supported by the Deutsche Forschungsgemeinschaft (KY96/1-1), Cologne fortune and cure SMA foundation.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>PJO, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>ICG, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>JB, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>EJLS, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>JS, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>NC, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>DL, Supervision, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>MJK, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>ACH, Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Invertebrate experimental procedures were carried out in accordance with the Brown University Institutional Animal Care and Use Committee (IACUC) guidelines, which adheres to the USDA: Animal Welfare Act &amp; Regulations and the Guide for the Care and Use of Laboratory Animals. The Brown University IACUC does not require permit or protocol approval for experiments involving invertebrate animals models. All mammalian experimental procedures were performed according to the institutional animal care committee guidelines of University of Cologne. Additionally, animal care and all surgical procedures were performed according to the institutional animal care committee guidelines and the German animal welfare laws and approved under the reference numbers 84-02.05.20.13.042 and UniKoeln_Anziege§4.16.020 of the LANUV (Landesamt für Natur, Umwelt und Verbraucherschutz NRW) state agency of North-Rhine-Westphalia.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD16-data"><object-id pub-id-type="doi">10.7554/eLife.20752.035</object-id><label>Supplementary file 1.</label><caption><title>Summary of <italic>C. elegans</italic> experiments.</title><p>(A) Summary of synaptic protein localization experiments; percent change from control for all metrics. (B) Summary of <italic>C. elegans</italic> phenotypes for selected loss of function alleles from this study as well as those identified in previous literature. <italic>Related to <xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig6">6</xref> and their figure supplements.</italic></p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.035">http://dx.doi.org/10.7554/eLife.20752.035</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="SD17-data"><object-id pub-id-type="doi">10.7554/eLife.20752.036</object-id><label>Supplementary file 2.</label><caption><title><italic>C. elegans</italic> strains and other materials utilized.</title><p>(A) Strains used for this work; related to materials and methods. (B) Primers and ssODNs used for this work; related to materials and methods. (C) Arrays/integrated lines/alleles with abbreviation in text and figures. </p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.20752.036">http://dx.doi.org/10.7554/eLife.20752.036</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-20752-supp2-v1.xlsx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abera</surname><given-names>MB</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Nofziger</surname><given-names>J</given-names></name><name><surname>Titus</surname><given-names>S</given-names></name><name><surname>Southall</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Moritz</surname><given-names>KE</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Cherry</surname><given-names>JJ</given-names></name><name><surname>Androphy</surname><given-names>EJ</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Austin</surname><given-names>C</given-names></name><name><surname>Fischbeck</surname><given-names>KH</given-names></name><name><surname>Marugan</surname><given-names>JJ</given-names></name><name><surname>Burnett</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice</article-title><source>JCI Insight</source><volume>1</volume><elocation-id>e88427</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.88427</pub-id><pub-id pub-id-type="pmid">27882347</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>CL</given-names></name><name><surname>Jensen</surname><given-names>JL</given-names></name><name><surname>Ørntoft</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and Colon cancer data sets</article-title><source>Cancer Research</source><volume>64</volume><fpage>5245</fpage><lpage>5250</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0496</pub-id><pub-id pub-id-type="pmid">15289330</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>The genetics of <italic>Caenorhabditis elegans</italic></article-title><source>Genetics</source><volume>77</volume><fpage>71</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">4366476</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briese</surname><given-names>M</given-names></name><name><surname>Esmaeili</surname><given-names>B</given-names></name><name><surname>Fraboulet</surname><given-names>S</given-names></name><name><surname>Burt</surname><given-names>EC</given-names></name><name><surname>Christodoulou</surname><given-names>S</given-names></name><name><surname>Towers</surname><given-names>PR</given-names></name><name><surname>Davies</surname><given-names>KE</given-names></name><name><surname>Sattelle</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Deletion of <italic>smn-1</italic>, the <italic>Caenorhabditis elegans</italic> ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan</article-title><source>Human Molecular Genetics</source><volume>18</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn320</pub-id><pub-id pub-id-type="pmid">18829666</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calixto</surname><given-names>A</given-names></name><name><surname>Chelur</surname><given-names>D</given-names></name><name><surname>Topalidou</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chalfie</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enhanced neuronal RNAi in <italic>C. elegans</italic> using SID-1</article-title><source>Nature Methods</source><volume>7</volume><fpage>554</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1463</pub-id><pub-id pub-id-type="pmid">20512143</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauchi</surname><given-names>RJ</given-names></name><name><surname>Davies</surname><given-names>KE</given-names></name><name><surname>Liu</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A motor function for the DEAD-box RNA helicase, Gemin3, in <italic>Drosophila</italic></article-title><source>PLoS Genetics</source><volume>4</volume><elocation-id>e1000265</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000265</pub-id><pub-id pub-id-type="pmid">19023405</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ch'ng</surname><given-names>Q</given-names></name><name><surname>Sieburth</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Profiling synaptic proteins identifies regulators of insulin secretion and lifespan</article-title><source>PLoS Genetics</source><volume>4</volume><elocation-id>e1000283</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000283</pub-id><pub-id pub-id-type="pmid">19043554</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charroux</surname><given-names>B</given-names></name><name><surname>Pellizzoni</surname><given-names>L</given-names></name><name><surname>Perkinson</surname><given-names>RA</given-names></name><name><surname>Shevchenko</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Gemin3: A novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems</article-title><source>The Journal of Cell Biology</source><volume>147</volume><fpage>1181</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1083/jcb.147.6.1181</pub-id><pub-id pub-id-type="pmid">10601333</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>SM</given-names></name><name><surname>Boyer</surname><given-names>SB</given-names></name><name><surname>Slesinger</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Coregulation of natively expressed pertussis toxin-sensitive muscarinic receptors with G-protein-activated potassium channels</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>6388</fpage><lpage>6399</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1190-07.2007</pub-id><pub-id pub-id-type="pmid">17567799</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloonan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Re-thinking miRNA-mRNA interactions: intertwining issues confound target discovery</article-title><source>BioEssays</source><volume>37</volume><fpage>379</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1002/bies.201400191</pub-id><pub-id pub-id-type="pmid">25683051</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulson</surname><given-names>EJ</given-names></name><name><surname>May</surname><given-names>LM</given-names></name><name><surname>Osborne</surname><given-names>SL</given-names></name><name><surname>Reid</surname><given-names>K</given-names></name><name><surname>Underwood</surname><given-names>CK</given-names></name><name><surname>Meunier</surname><given-names>FA</given-names></name><name><surname>Bartlett</surname><given-names>PF</given-names></name><name><surname>Sah</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>p75 neurotrophin receptor mediates neuronal cell death by activating GIRK channels through phosphatidylinositol 4,5-bisphosphate</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2699-07.2008</pub-id><pub-id pub-id-type="pmid">18171948</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusin</surname><given-names>V</given-names></name><name><surname>Clermont</surname><given-names>O</given-names></name><name><surname>Gérard</surname><given-names>B</given-names></name><name><surname>Chantereau</surname><given-names>D</given-names></name><name><surname>Elion</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling</article-title><source>Journal of Medical Genetics</source><volume>40</volume><elocation-id>e39</elocation-id><lpage>39</lpage><pub-id pub-id-type="doi">10.1136/jmg.40.4.e39</pub-id><pub-id pub-id-type="pmid">12676912</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deardorff</surname><given-names>AS</given-names></name><name><surname>Romer</surname><given-names>SH</given-names></name><name><surname>Sonner</surname><given-names>PM</given-names></name><name><surname>Fyffe</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Swimming against the tide: investigations of the C-bouton synapse</article-title><source>Frontiers in Neural Circuits</source><volume>8</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2014.00106</pub-id><pub-id pub-id-type="pmid">25278842</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>DJ</given-names></name><name><surname>Pani</surname><given-names>AM</given-names></name><name><surname>Heppert</surname><given-names>JK</given-names></name><name><surname>Higgins</surname><given-names>CD</given-names></name><name><surname>Goldstein</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Streamlined Genome Engineering with a Self-Excising Drug selection cassette</article-title><source>Genetics</source><volume>200</volume><fpage>1035</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1534/genetics.115.178335</pub-id><pub-id pub-id-type="pmid">26044593</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitriadi</surname><given-names>M</given-names></name><name><surname>Sleigh</surname><given-names>JN</given-names></name><name><surname>Walker</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>HC</given-names></name><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Kalloo</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Barsby</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>MB</given-names></name><name><surname>Satterlee</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Van Vactor</surname><given-names>D</given-names></name><name><surname>Artavanis-Tsakonas</surname><given-names>S</given-names></name><name><surname>Hart</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Conserved genes act as modifiers of Invertebrate SMN loss of function defects</article-title><source>PLoS Genetics</source><volume>6</volume><elocation-id>e1001172</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001172</pub-id><pub-id pub-id-type="pmid">21124729</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitriadi</surname><given-names>M</given-names></name><name><surname>Kye</surname><given-names>MJ</given-names></name><name><surname>Kalloo</surname><given-names>G</given-names></name><name><surname>Yersak</surname><given-names>JM</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name><name><surname>Hart</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>6557</fpage><lpage>6562</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1536-12.2013</pub-id><pub-id pub-id-type="pmid">23575853</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitriadi</surname><given-names>M</given-names></name><name><surname>Derdowski</surname><given-names>A</given-names></name><name><surname>Kalloo</surname><given-names>G</given-names></name><name><surname>Maginnis</surname><given-names>MS</given-names></name><name><surname>O'Hern</surname><given-names>P</given-names></name><name><surname>Bliska</surname><given-names>B</given-names></name><name><surname>Sorkaç</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>KC</given-names></name><name><surname>Cook</surname><given-names>SJ</given-names></name><name><surname>Poulogiannis</surname><given-names>G</given-names></name><name><surname>Atwood</surname><given-names>WJ</given-names></name><name><surname>Hall</surname><given-names>DH</given-names></name><name><surname>Hart</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Decreased function of survival motor neuron protein impairs endocytic pathways</article-title><source>PNAS</source><volume>113</volume><fpage>E4377</fpage><lpage>E4386</lpage><pub-id pub-id-type="doi">10.1073/pnas.1600015113</pub-id><pub-id pub-id-type="pmid">27402754</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittman</surname><given-names>JS</given-names></name><name><surname>Kaplan</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Behavioral impact of neurotransmitter-activated G-protein-coupled receptors: muscarinic and GABAB receptors regulate <italic>Caenorhabditis elegans</italic> locomotion</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>7104</fpage><lpage>7112</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0378-08.2008</pub-id><pub-id pub-id-type="pmid">18614679</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dostie</surname><given-names>J</given-names></name><name><surname>Mourelatos</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Numerous microRNPs in neuronal cells containing novel microRNAs</article-title><source>RNA</source><volume>9</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1261/rna.2141503</pub-id><pub-id pub-id-type="pmid">12554860</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudel</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The time course of transmitter release in mouse motor nerve terminals is differentially affected by activation of muscarinic M1 or M2 receptors</article-title><source>European Journal of Neuroscience</source><volume>26</volume><fpage>2160</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05770.x</pub-id><pub-id pub-id-type="pmid">17953614</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbashir</surname><given-names>SM</given-names></name><name><surname>Harborth</surname><given-names>J</given-names></name><name><surname>Lendeckel</surname><given-names>W</given-names></name><name><surname>Yalcin</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>K</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells</article-title><source>Nature</source><volume>411</volume><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/35078107</pub-id><pub-id pub-id-type="pmid">11373684</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essers</surname><given-names>PB</given-names></name><name><surname>Nonnekens</surname><given-names>J</given-names></name><name><surname>Goos</surname><given-names>YJ</given-names></name><name><surname>Betist</surname><given-names>MC</given-names></name><name><surname>Viester</surname><given-names>MD</given-names></name><name><surname>Mossink</surname><given-names>B</given-names></name><name><surname>Lansu</surname><given-names>N</given-names></name><name><surname>Korswagen</surname><given-names>HC</given-names></name><name><surname>Jelier</surname><given-names>R</given-names></name><name><surname>Brenkman</surname><given-names>AB</given-names></name><name><surname>MacInnes</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A long noncoding RNA on the ribosome is required for lifespan extension</article-title><source>Cell Reports</source><volume>10</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.029</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallini</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Silani</surname><given-names>V</given-names></name><name><surname>Singer</surname><given-names>RH</given-names></name><name><surname>Rossoll</surname><given-names>W</given-names></name><name><surname>Bassell</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons</article-title><source>Journal of Neuroscience</source><volume>31</volume><fpage>3914</fpage><lpage>3925</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3631-10.2011</pub-id><pub-id pub-id-type="pmid">21389246</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Gubitz</surname><given-names>AK</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Battle</surname><given-names>DJ</given-names></name><name><surname>Dostie</surname><given-names>J</given-names></name><name><surname>Golembe</surname><given-names>TJ</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gemins modulate the expression and activity of the SMN complex</article-title><source>Human Molecular Genetics</source><volume>14</volume><fpage>1605</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi168</pub-id><pub-id pub-id-type="pmid">15843395</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firnhaber</surname><given-names>C</given-names></name><name><surname>Hammarlund</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neuron-specific feeding RNAi in <italic>C. elegans</italic> and its use in a screen for essential genes required for GABA neuron function</article-title><source>PLoS Genetics</source><volume>9</volume><elocation-id>e1003921</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003921</pub-id><pub-id pub-id-type="pmid">24244189</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>MA</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name><name><surname>Borza</surname><given-names>DB</given-names></name><name><surname>Eswarakumar</surname><given-names>VP</given-names></name><name><surname>Fässler</surname><given-names>R</given-names></name><name><surname>Hudson</surname><given-names>BG</given-names></name><name><surname>John</surname><given-names>SW</given-names></name><name><surname>Ninomiya</surname><given-names>Y</given-names></name><name><surname>Pedchenko</surname><given-names>V</given-names></name><name><surname>Pfaff</surname><given-names>SL</given-names></name><name><surname>Rheault</surname><given-names>MN</given-names></name><name><surname>Sado</surname><given-names>Y</given-names></name><name><surname>Segal</surname><given-names>Y</given-names></name><name><surname>Werle</surname><given-names>MJ</given-names></name><name><surname>Umemori</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals</article-title><source>Cell</source><volume>129</volume><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.02.035</pub-id><pub-id pub-id-type="pmid">17418794</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedland</surname><given-names>AE</given-names></name><name><surname>Tzur</surname><given-names>YB</given-names></name><name><surname>Esvelt</surname><given-names>KM</given-names></name><name><surname>Colaiácovo</surname><given-names>MP</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name><name><surname>Calarco</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Heritable genome editing in <italic>C. elegans</italic> via a CRISPR-Cas9 system</article-title><source>Nature Methods</source><volume>10</volume><fpage>741</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2532</pub-id><pub-id pub-id-type="pmid">23817069</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frøkjaer-Jensen</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>MW</given-names></name><name><surname>Hopkins</surname><given-names>CE</given-names></name><name><surname>Newman</surname><given-names>BJ</given-names></name><name><surname>Thummel</surname><given-names>JM</given-names></name><name><surname>Olesen</surname><given-names>SP</given-names></name><name><surname>Grunnet</surname><given-names>M</given-names></name><name><surname>Jorgensen</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Single-copy insertion of transgenes in <italic>Caenorhabditis elegans</italic></article-title><source>Nature Genetics</source><volume>40</volume><fpage>1375</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1038/ng.248</pub-id><pub-id pub-id-type="pmid">18953339</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>JA</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Control of spontaneous firing patterns by the selective coupling of calcium currents to calcium-activated potassium currents in striatal cholinergic interneurons</article-title><source>Journal of Neuroscience</source><volume>25</volume><fpage>10230</fpage><lpage>10238</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2734-05.2005</pub-id><pub-id pub-id-type="pmid">16267230</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golembe</surname><given-names>TJ</given-names></name><name><surname>Yong</surname><given-names>J</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Specific sequence features, recognized by the SMN complex, identify snRNAs and determine their fate as snRNPs</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>10989</fpage><lpage>11004</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.24.10989-11004.2005</pub-id><pub-id pub-id-type="pmid">16314521</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosso</surname><given-names>FM</given-names></name><name><surname>de Geus</surname><given-names>EJ</given-names></name><name><surname>Polderman</surname><given-names>TJ</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Exploring the functional role of the CHRM2 gene in human cognition: results from a dense genotyping and brain expression study</article-title><source>BMC Medical Genetics</source><volume>8</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2350-8-66</pub-id><pub-id pub-id-type="pmid">17996044</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grishok</surname><given-names>A</given-names></name><name><surname>Pasquinelli</surname><given-names>AE</given-names></name><name><surname>Conte</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Parrish</surname><given-names>S</given-names></name><name><surname>Ha</surname><given-names>I</given-names></name><name><surname>Baillie</surname><given-names>DL</given-names></name><name><surname>Fire</surname><given-names>A</given-names></name><name><surname>Ruvkun</surname><given-names>G</given-names></name><name><surname>Mello</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control <italic>C. elegans</italic> developmental timing</article-title><source>Cell</source><volume>106</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00431-7</pub-id><pub-id pub-id-type="pmid">11461699</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haramati</surname><given-names>S</given-names></name><name><surname>Chapnik</surname><given-names>E</given-names></name><name><surname>Sztainberg</surname><given-names>Y</given-names></name><name><surname>Eilam</surname><given-names>R</given-names></name><name><surname>Zwang</surname><given-names>R</given-names></name><name><surname>Gershoni</surname><given-names>N</given-names></name><name><surname>McGlinn</surname><given-names>E</given-names></name><name><surname>Heiser</surname><given-names>PW</given-names></name><name><surname>Wills</surname><given-names>AM</given-names></name><name><surname>Wirguin</surname><given-names>I</given-names></name><name><surname>Rubin</surname><given-names>LL</given-names></name><name><surname>Misawa</surname><given-names>H</given-names></name><name><surname>Tabin</surname><given-names>CJ</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Hornstein</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>miRNA malfunction causes spinal motor neuron disease</article-title><source>PNAS</source><volume>107</volume><fpage>13111</fpage><lpage>13116</lpage><pub-id pub-id-type="doi">10.1073/pnas.1006151107</pub-id><pub-id pub-id-type="pmid">20616011</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helmken</surname><given-names>C</given-names></name><name><surname>Hofmann</surname><given-names>Y</given-names></name><name><surname>Schoenen</surname><given-names>F</given-names></name><name><surname>Oprea</surname><given-names>G</given-names></name><name><surname>Raschke</surname><given-names>H</given-names></name><name><surname>Rudnik-Schöneborn</surname><given-names>S</given-names></name><name><surname>Zerres</surname><given-names>K</given-names></name><name><surname>Wirth</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1</article-title><source>Human Genetics</source><volume>114</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s00439-003-1025-2</pub-id><pub-id pub-id-type="pmid">14520560</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseinibarkooie</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Torres-Benito</surname><given-names>L</given-names></name><name><surname>Rastetter</surname><given-names>RH</given-names></name><name><surname>Hupperich</surname><given-names>K</given-names></name><name><surname>Hoffmann</surname><given-names>A</given-names></name><name><surname>Mendoza-Ferreira</surname><given-names>N</given-names></name><name><surname>Kaczmarek</surname><given-names>A</given-names></name><name><surname>Janzen</surname><given-names>E</given-names></name><name><surname>Milbradt</surname><given-names>J</given-names></name><name><surname>Lamkemeyer</surname><given-names>T</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Guschlbauer</surname><given-names>C</given-names></name><name><surname>Büschges</surname><given-names>A</given-names></name><name><surname>Hammerschmidt</surname><given-names>M</given-names></name><name><surname>Riessland</surname><given-names>M</given-names></name><name><surname>Kye</surname><given-names>MJ</given-names></name><name><surname>Clemen</surname><given-names>CS</given-names></name><name><surname>Wirth</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The power of human protective modifiers: pls3 and CORO1C Unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype</article-title><source>The American Journal of Human Genetics</source><volume>99</volume><fpage>647</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.07.014</pub-id><pub-id pub-id-type="pmid">27499521</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchins</surname><given-names>BI</given-names></name><name><surname>Kalil</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Differential outgrowth of axons and their branches is regulated by localized calcium transients</article-title><source>Journal of Neuroscience</source><volume>28</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4548-07.2008</pub-id><pub-id pub-id-type="pmid">18171932</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutvágner</surname><given-names>G</given-names></name><name><surname>Zamore</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A microRNA in a multiple-turnover RNAi enzyme complex</article-title><source>Science</source><volume>297</volume><fpage>2056</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1126/science.1073827</pub-id><pub-id pub-id-type="pmid">12154197</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Höck</surname><given-names>J</given-names></name><name><surname>Weinmann</surname><given-names>L</given-names></name><name><surname>Ender</surname><given-names>C</given-names></name><name><surname>Rüdel</surname><given-names>S</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Raabe</surname><given-names>M</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Meister</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells</article-title><source>EMBO Reports</source><volume>8</volume><fpage>1052</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7401088</pub-id><pub-id pub-id-type="pmid">17932509</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibáñez-Ventoso</surname><given-names>C</given-names></name><name><surname>Vora</surname><given-names>M</given-names></name><name><surname>Driscoll</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sequence relationships among <italic>C. elegans</italic>, <italic>D. Melanogaster</italic> and human microRNAs highlight the extensive conservation of microRNAs in biology</article-title><source>PLoS ONE</source><volume>3</volume><elocation-id>e2818</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002818</pub-id><pub-id pub-id-type="pmid">18665242</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jablonka</surname><given-names>S</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name><name><surname>Lechner</surname><given-names>BD</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Sendtner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy</article-title><source>The Journal of Cell Biology</source><volume>179</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1083/jcb.200703187</pub-id><pub-id pub-id-type="pmid">17923533</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>CH</given-names></name><name><surname>Friedman</surname><given-names>RC</given-names></name><name><surname>Ruby</surname><given-names>JG</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Formation, regulation and evolution of <italic>Caenorhabditis elegans</italic> 3'UTRs</article-title><source>Nature</source><volume>469</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/nature09616</pub-id><pub-id pub-id-type="pmid">21085120</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>RS</given-names></name><name><surname>Ahringer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Genome-wide RNAi screening in <italic>Caenorhabditis elegans</italic></article-title><source>Methods</source><volume>30</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/S1046-2023(03)00050-1</pub-id><pub-id pub-id-type="pmid">12828945</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamikura</surname><given-names>DM</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Clathrin interaction and subcellular localization of Ce-DAB-1, an adaptor for protein secretion in <italic>Caenorhabditis elegans</italic></article-title><source>Traffic</source><volume>7</volume><fpage>324</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2006.00386.x</pub-id><pub-id pub-id-type="pmid">16497226</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Ruvkun</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A conserved siRNA-degrading RNase negatively regulates RNA interference in <italic>C. elegans</italic></article-title><source>Nature</source><volume>427</volume><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1038/nature02302</pub-id><pub-id pub-id-type="pmid">14961122</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Lilley</surname><given-names>BN</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name><name><surname>Zhen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A chemical-genetic strategy reveals distinct temporal requirements for SAD-1 kinase in neuronal polarization and synapse formation</article-title><source>Neural Development</source><volume>3</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1186/1749-8104-3-23</pub-id><pub-id pub-id-type="pmid">18808695</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Choe</surname><given-names>DW</given-names></name><name><surname>Polley</surname><given-names>M</given-names></name><name><surname>Burnett</surname><given-names>BG</given-names></name><name><surname>Bosch-Marcé</surname><given-names>M</given-names></name><name><surname>Griffin</surname><given-names>JW</given-names></name><name><surname>Rich</surname><given-names>MM</given-names></name><name><surname>Sumner</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice</article-title><source>Journal of Neuroscience</source><volume>29</volume><fpage>842</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4434-08.2009</pub-id><pub-id pub-id-type="pmid">19158308</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurrasch</surname><given-names>DM</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wilkie</surname><given-names>TM</given-names></name><name><surname>Repa</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Quantitative real-time polymerase chain reaction measurement of regulators of G-protein signaling mRNA levels in mouse tissues</article-title><source>Methods in Enzymology</source><volume>389</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(04)89001-3</pub-id><pub-id pub-id-type="pmid">15313556</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kye</surname><given-names>MJ</given-names></name><name><surname>Niederst</surname><given-names>ED</given-names></name><name><surname>Wertz</surname><given-names>MH</given-names></name><name><surname>Gonçalves</surname><given-names>IC</given-names></name><name><surname>Akten</surname><given-names>B</given-names></name><name><surname>Dover</surname><given-names>KZ</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Riessland</surname><given-names>M</given-names></name><name><surname>Neveu</surname><given-names>P</given-names></name><name><surname>Wirth</surname><given-names>B</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name><name><surname>Sardi</surname><given-names>SP</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name><name><surname>Passini</surname><given-names>MA</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>SMN regulates axonal local translation via miR-183/mTOR pathway</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>6318</fpage><lpage>6331</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu350</pub-id><pub-id pub-id-type="pmid">25055867</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Suh</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kaang</surname><given-names>BK</given-names></name><name><surname>Cho</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Characterization of GAR-2, a novel G protein-linked acetylcholine receptor from <italic>Caenorhabditis elegans</italic></article-title><source>Journal of Neurochemistry</source><volume>75</volume><fpage>1800</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0751800.x</pub-id><pub-id pub-id-type="pmid">11032868</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>S</given-names></name><name><surname>Bürglen</surname><given-names>L</given-names></name><name><surname>Reboullet</surname><given-names>S</given-names></name><name><surname>Clermont</surname><given-names>O</given-names></name><name><surname>Burlet</surname><given-names>P</given-names></name><name><surname>Viollet</surname><given-names>L</given-names></name><name><surname>Benichou</surname><given-names>B</given-names></name><name><surname>Cruaud</surname><given-names>C</given-names></name><name><surname>Millasseau</surname><given-names>P</given-names></name><name><surname>Zeviani</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Identification and characterization of a spinal muscular atrophy-determining gene</article-title><source>Cell</source><volume>80</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90460-3</pub-id><pub-id pub-id-type="pmid">7813012</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>S</given-names></name><name><surname>Burlet</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Bertrandy</surname><given-names>S</given-names></name><name><surname>Clermont</surname><given-names>O</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name><name><surname>Melki</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Correlation between severity and SMN protein level in spinal muscular atrophy</article-title><source>Nature Genetics</source><volume>16</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/ng0797-265</pub-id><pub-id pub-id-type="pmid">9207792</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title><source>Cell</source><volume>120</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.12.035</pub-id><pub-id pub-id-type="pmid">15652477</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>K</given-names></name><name><surname>Reid</surname><given-names>SJ</given-names></name><name><surname>Snell</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rapid RNA analysis of individual <italic>Caenorhabditis elegans</italic></article-title><source>MethodsX</source><volume>2</volume><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.mex.2015.02.002</pub-id><pub-id pub-id-type="pmid">26150972</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>TR</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Nonet</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Analysis of synaptic transmission in <italic>Caenorhabditis elegans</italic> using an aldicarb-sensitivity assay</article-title><source>Nature Protocols</source><volume>1</volume><fpage>1772</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.281</pub-id><pub-id pub-id-type="pmid">17487159</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marco</surname><given-names>A</given-names></name><name><surname>Hooks</surname><given-names>K</given-names></name><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Evolution and function of the extended miR-2 microRNA family</article-title><source>RNA Biology</source><volume>9</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.4161/rna.19160</pub-id><pub-id pub-id-type="pmid">22336713</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>NJ</given-names></name><name><surname>Ow</surname><given-names>MC</given-names></name><name><surname>Reece-Hoyes</surname><given-names>JS</given-names></name><name><surname>Barrasa</surname><given-names>MI</given-names></name><name><surname>Ambros</surname><given-names>VR</given-names></name><name><surname>Walhout</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genome-scale spatiotemporal analysis of <italic>Caenorhabditis elegans</italic> microRNA promoter activity</article-title><source>Genome Research</source><volume>18</volume><fpage>2005</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1101/gr.083055.108</pub-id><pub-id pub-id-type="pmid">18981266</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McWhorter</surname><given-names>ML</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name><name><surname>Burghes</surname><given-names>AH</given-names></name><name><surname>Beattie</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding</article-title><source>The Journal of Cell Biology</source><volume>162</volume><fpage>919</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1083/jcb.200303168</pub-id><pub-id pub-id-type="pmid">12952942</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>G</given-names></name><name><surname>Eggert</surname><given-names>C</given-names></name><name><surname>Bühler</surname><given-names>D</given-names></name><name><surname>Brahms</surname><given-names>H</given-names></name><name><surname>Kambach</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Methylation of sm proteins by a complex containing PRMT5 and the Putative U snRNP assembly factor pICln</article-title><source>Current Biology</source><volume>11</volume><fpage>1990</fpage><lpage>1994</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(01)00592-9</pub-id><pub-id pub-id-type="pmid">11747828</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>G</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Lührmann</surname><given-names>R</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Identification of novel argonaute-associated proteins</article-title><source>Current Biology</source><volume>15</volume><fpage>2149</fpage><lpage>2155</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.10.048</pub-id><pub-id pub-id-type="pmid">16289642</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miguel-Aliaga</surname><given-names>I</given-names></name><name><surname>Culetto</surname><given-names>E</given-names></name><name><surname>Walker</surname><given-names>DS</given-names></name><name><surname>Baylis</surname><given-names>HA</given-names></name><name><surname>Sattelle</surname><given-names>DB</given-names></name><name><surname>Davies</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The <italic>Caenorhabditis elegans</italic> orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability</article-title><source>Human Molecular Genetics</source><volume>8</volume><fpage>2133</fpage><lpage>2143</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.12.2133</pub-id><pub-id pub-id-type="pmid">10545592</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minasaki</surname><given-names>R</given-names></name><name><surname>Puoti</surname><given-names>A</given-names></name><name><surname>Streit</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The DEAD-box protein MEL-46 is required in the germ line of the nematode <italic>Caenorhabditis elegans</italic></article-title><source>BMC Developmental Biology</source><volume>9</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1186/1471-213X-9-35</pub-id><pub-id pub-id-type="pmid">19534797</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mourelatos</surname><given-names>Z</given-names></name><name><surname>Dostie</surname><given-names>J</given-names></name><name><surname>Paushkin</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Charroux</surname><given-names>B</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Rappsilber</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs</article-title><source>Genes and Development</source><volume>16</volume><fpage>720</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1101/gad.974702</pub-id><pub-id pub-id-type="pmid">11914277</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murashov</surname><given-names>AK</given-names></name><name><surname>Chintalgattu</surname><given-names>V</given-names></name><name><surname>Islamov</surname><given-names>RR</given-names></name><name><surname>Lever</surname><given-names>TE</given-names></name><name><surname>Pak</surname><given-names>ES</given-names></name><name><surname>Sierpinski</surname><given-names>PL</given-names></name><name><surname>Katwa</surname><given-names>LC</given-names></name><name><surname>Van Scott</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>RNAi pathway is functional in peripheral nerve axons</article-title><source>The FASEB Journal</source><volume>21</volume><fpage>656</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1096/fj.06-6155com</pub-id><pub-id pub-id-type="pmid">17209129</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimune</surname><given-names>H</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name><name><surname>Carlson</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals</article-title><source>Nature</source><volume>432</volume><fpage>580</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1038/nature03112</pub-id><pub-id pub-id-type="pmid">15577901</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonet</surname><given-names>ML</given-names></name><name><surname>Saifee</surname><given-names>O</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Rand</surname><given-names>JB</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Synaptic transmission deficits in <italic>Caenorhabditis elegans</italic> synaptobrevin mutants</article-title><source>Journal of Neuroscience</source><volume>18</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">9412487</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraskevopoulou</surname><given-names>MD</given-names></name><name><surname>Georgakilas</surname><given-names>G</given-names></name><name><surname>Kostoulas</surname><given-names>N</given-names></name><name><surname>Vlachos</surname><given-names>IS</given-names></name><name><surname>Vergoulis</surname><given-names>T</given-names></name><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Filippidis</surname><given-names>C</given-names></name><name><surname>Dalamagas</surname><given-names>T</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>W169</fpage><lpage>W173</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt393</pub-id><pub-id pub-id-type="pmid">23680784</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnas</surname><given-names>H</given-names></name><name><surname>Slutsky</surname><given-names>I</given-names></name><name><surname>Rashkovan</surname><given-names>G</given-names></name><name><surname>Silman</surname><given-names>I</given-names></name><name><surname>Wess</surname><given-names>J</given-names></name><name><surname>Parnas</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Depolarization initiates phasic acetylcholine release by relief of a tonic block imposed by presynaptic M2 muscarinic receptors</article-title><source>Journal of Neurophysiology</source><volume>93</volume><fpage>3257</fpage><lpage>3269</lpage><pub-id pub-id-type="doi">10.1152/jn.01131.2004</pub-id><pub-id pub-id-type="pmid">15703226</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearn</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy</article-title><source>Journal of Medical Genetics</source><volume>15</volume><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1136/jmg.15.6.409</pub-id><pub-id pub-id-type="pmid">745211</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellizzoni</surname><given-names>L</given-names></name><name><surname>Yong</surname><given-names>J</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Essential role for the SMN complex in the specificity of snRNP assembly</article-title><source>Science</source><volume>298</volume><fpage>1775</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1126/science.1074962</pub-id><pub-id pub-id-type="pmid">12459587</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powis</surname><given-names>RA</given-names></name><name><surname>Gillingwater</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy</article-title><source>Journal of Anatomy</source><volume>228</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/joa.12419</pub-id><pub-id pub-id-type="pmid">26576026</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Maragkakis</surname><given-names>M</given-names></name><name><surname>Alexiou</surname><given-names>P</given-names></name><name><surname>Grosse</surname><given-names>I</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Functional microRNA targets in protein coding sequences</article-title><source>Bioinformatics</source><volume>28</volume><fpage>771</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts043</pub-id><pub-id pub-id-type="pmid">22285563</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riessland</surname><given-names>M</given-names></name><name><surname>Ackermann</surname><given-names>B</given-names></name><name><surname>Förster</surname><given-names>A</given-names></name><name><surname>Jakubik</surname><given-names>M</given-names></name><name><surname>Hauke</surname><given-names>J</given-names></name><name><surname>Garbes</surname><given-names>L</given-names></name><name><surname>Fritzsche</surname><given-names>I</given-names></name><name><surname>Mende</surname><given-names>Y</given-names></name><name><surname>Blumcke</surname><given-names>I</given-names></name><name><surname>Hahnen</surname><given-names>E</given-names></name><name><surname>Wirth</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy</article-title><source>Human Molecular Genetics</source><volume>19</volume><fpage>1492</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq023</pub-id><pub-id pub-id-type="pmid">20097677</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossoll</surname><given-names>W</given-names></name><name><surname>Jablonka</surname><given-names>S</given-names></name><name><surname>Andreassi</surname><given-names>C</given-names></name><name><surname>Kröning</surname><given-names>AK</given-names></name><name><surname>Karle</surname><given-names>K</given-names></name><name><surname>Monani</surname><given-names>UR</given-names></name><name><surname>Sendtner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons</article-title><source>The Journal of Cell Biology</source><volume>163</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1083/jcb.200304128</pub-id><pub-id pub-id-type="pmid">14623865</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Ernstrom</surname><given-names>GG</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Weimer</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Jorgensen</surname><given-names>EM</given-names></name><name><surname>Grant</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Differential requirements for clathrin in receptor-mediated endocytosis and maintenance of synaptic vesicle pools</article-title><source>PNAS</source><volume>106</volume><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809541106</pub-id><pub-id pub-id-type="pmid">19151157</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Schwanhäusser</surname><given-names>B</given-names></name><name><surname>Thierfelder</surname><given-names>N</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Rajewsky</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Widespread changes in protein synthesis induced by microRNAs</article-title><source>Nature</source><volume>455</volume><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature07228</pub-id><pub-id pub-id-type="pmid">18668040</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieburth</surname><given-names>D</given-names></name><name><surname>Ch'ng</surname><given-names>Q</given-names></name><name><surname>Dybbs</surname><given-names>M</given-names></name><name><surname>Tavazoie</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Dupuy</surname><given-names>D</given-names></name><name><surname>Rual</surname><given-names>JF</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Ruvkun</surname><given-names>G</given-names></name><name><surname>Kaplan</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Systematic analysis of genes required for synapse structure and function</article-title><source>Nature</source><volume>436</volume><fpage>510</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nature03809</pub-id><pub-id pub-id-type="pmid">16049479</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simard</surname><given-names>LR</given-names></name><name><surname>Bélanger</surname><given-names>MC</given-names></name><name><surname>Morissette</surname><given-names>S</given-names></name><name><surname>Wride</surname><given-names>M</given-names></name><name><surname>Prior</surname><given-names>TW</given-names></name><name><surname>Swoboda</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA</article-title><source>Neurology</source><volume>68</volume><fpage>451</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000252934.70676.ab</pub-id><pub-id pub-id-type="pmid">17283322</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleigh</surname><given-names>JN</given-names></name><name><surname>Buckingham</surname><given-names>SD</given-names></name><name><surname>Esmaeili</surname><given-names>B</given-names></name><name><surname>Viswanathan</surname><given-names>M</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name><name><surname>Westlund</surname><given-names>BM</given-names></name><name><surname>Sattelle</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A novel <italic>Caenorhabditis elegans</italic> allele, <italic>smn-1(cb131)</italic>, mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds</article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>245</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq459</pub-id><pub-id pub-id-type="pmid">20962036</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slutsky</surname><given-names>I</given-names></name><name><surname>Wess</surname><given-names>J</given-names></name><name><surname>Gomeza</surname><given-names>J</given-names></name><name><surname>Dudel</surname><given-names>J</given-names></name><name><surname>Parnas</surname><given-names>I</given-names></name><name><surname>Parnas</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Use of knockout mice reveals involvement of M2-muscarinic receptors in control of the kinetics of acetylcholine release</article-title><source>Journal of Neurophysiology</source><volume>89</volume><fpage>1954</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1152/jn.00668.2002</pub-id><pub-id pub-id-type="pmid">12686574</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>BN</given-names></name><name><surname>Ticozzi</surname><given-names>N</given-names></name><name><surname>Fallini</surname><given-names>C</given-names></name><name><surname>Gkazi</surname><given-names>AS</given-names></name><name><surname>Topp</surname><given-names>S</given-names></name><name><surname>Kenna</surname><given-names>KP</given-names></name><name><surname>Scotter</surname><given-names>EL</given-names></name><name><surname>Kost</surname><given-names>J</given-names></name><name><surname>Keagle</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name><name><surname>Calini</surname><given-names>D</given-names></name><name><surname>Vance</surname><given-names>C</given-names></name><name><surname>Danielson</surname><given-names>EW</given-names></name><name><surname>Troakes</surname><given-names>C</given-names></name><name><surname>Tiloca</surname><given-names>C</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>EA</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Colombrita</surname><given-names>C</given-names></name><name><surname>Pensato</surname><given-names>V</given-names></name><name><surname>Castellotti</surname><given-names>B</given-names></name><name><surname>de Belleroche</surname><given-names>J</given-names></name><name><surname>Baas</surname><given-names>F</given-names></name><name><surname>ten Asbroek</surname><given-names>AL</given-names></name><name><surname>Sapp</surname><given-names>PC</given-names></name><name><surname>McKenna-Yasek</surname><given-names>D</given-names></name><name><surname>McLaughlin</surname><given-names>RL</given-names></name><name><surname>Polak</surname><given-names>M</given-names></name><name><surname>Asress</surname><given-names>S</given-names></name><name><surname>Esteban-Pérez</surname><given-names>J</given-names></name><name><surname>Muñoz-Blanco</surname><given-names>JL</given-names></name><name><surname>Simpson</surname><given-names>M</given-names></name><name><surname>van Rheenen</surname><given-names>W</given-names></name><name><surname>Diekstra</surname><given-names>FP</given-names></name><name><surname>Lauria</surname><given-names>G</given-names></name><name><surname>Duga</surname><given-names>S</given-names></name><name><surname>Corti</surname><given-names>S</given-names></name><name><surname>Cereda</surname><given-names>C</given-names></name><name><surname>Corrado</surname><given-names>L</given-names></name><name><surname>Sorarù</surname><given-names>G</given-names></name><name><surname>Morrison</surname><given-names>KE</given-names></name><name><surname>Williams</surname><given-names>KL</given-names></name><name><surname>Nicholson</surname><given-names>GA</given-names></name><name><surname>Blair</surname><given-names>IP</given-names></name><name><surname>Dion</surname><given-names>PA</given-names></name><name><surname>Leblond</surname><given-names>CS</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Hardiman</surname><given-names>O</given-names></name><name><surname>Veldink</surname><given-names>JH</given-names></name><name><surname>van den Berg</surname><given-names>LH</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Pall</surname><given-names>H</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Turner</surname><given-names>MR</given-names></name><name><surname>Talbot</surname><given-names>K</given-names></name><name><surname>Taroni</surname><given-names>F</given-names></name><name><surname>García-Redondo</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Glass</surname><given-names>JD</given-names></name><name><surname>Gellera</surname><given-names>C</given-names></name><name><surname>Ratti</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>RH</given-names></name><name><surname>Silani</surname><given-names>V</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Landers</surname><given-names>JE</given-names></name><collab>SLAGEN Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS</article-title><source>Neuron</source><volume>84</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.09.027</pub-id><pub-id pub-id-type="pmid">25374358</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YG</given-names></name><name><surname>Pita-Almenar</surname><given-names>JD</given-names></name><name><surname>Wu</surname><given-names>CS</given-names></name><name><surname>Renger</surname><given-names>JJ</given-names></name><name><surname>Uebele</surname><given-names>VN</given-names></name><name><surname>Lu</surname><given-names>HC</given-names></name><name><surname>Beierlein</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Biphasic cholinergic synaptic transmission controls action potential activity in thalamic reticular nucleus neurons</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>2048</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3177-12.2013</pub-id><pub-id pub-id-type="pmid">23365242</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>CL</given-names></name><name><surname>Plotkin</surname><given-names>JL</given-names></name><name><surname>Venø</surname><given-names>MT</given-names></name><name><surname>von Schimmelmann</surname><given-names>M</given-names></name><name><surname>Feinberg</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>S</given-names></name><name><surname>Handler</surname><given-names>A</given-names></name><name><surname>Kjems</surname><given-names>J</given-names></name><name><surname>Surmeier</surname><given-names>DJ</given-names></name><name><surname>O'Carroll</surname><given-names>D</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MicroRNA-128 governs neuronal excitability and motor behavior in mice</article-title><source>Science</source><volume>342</volume><fpage>1254</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1126/science.1244193</pub-id><pub-id pub-id-type="pmid">24311694</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarabal</surname><given-names>O</given-names></name><name><surname>Caraballo-Miralles</surname><given-names>V</given-names></name><name><surname>Cardona-Rossinyol</surname><given-names>A</given-names></name><name><surname>Correa</surname><given-names>FJ</given-names></name><name><surname>Olmos</surname><given-names>G</given-names></name><name><surname>Lladó</surname><given-names>J</given-names></name><name><surname>Esquerda</surname><given-names>JE</given-names></name><name><surname>Calderó</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>73</volume><fpage>519</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1097/NEN.0000000000000074</pub-id><pub-id pub-id-type="pmid">24806302</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>AG</given-names></name><name><surname>Morse</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>DJ</given-names></name><name><surname>McGinley</surname><given-names>S</given-names></name><name><surname>Stebbings</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>SMN, Gemin2 and Gemin3 associate with beta-actin mRNA in the cytoplasm of neuronal cells in vitro</article-title><source>Journal of Molecular Biology</source><volume>401</volume><fpage>681</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2010.06.058</pub-id><pub-id pub-id-type="pmid">20620147</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>AG</given-names></name><name><surname>Shaw</surname><given-names>DJ</given-names></name><name><surname>Morse</surname><given-names>R</given-names></name><name><surname>Stebbings</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>SMN and the gemin proteins form sub-complexes that localise to both stationary and dynamic neurite granules</article-title><source>Biochemical and Biophysical Research Communications</source><volume>394</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.02.158</pub-id><pub-id pub-id-type="pmid">20188701</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valsecchi</surname><given-names>V</given-names></name><name><surname>Boido</surname><given-names>M</given-names></name><name><surname>De Amicis</surname><given-names>E</given-names></name><name><surname>Piras</surname><given-names>A</given-names></name><name><surname>Vercelli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expression of Muscle-Specific MiRNA 206 in the progression of disease in a Murine SMA Model</article-title><source>PLoS One</source><volume>10</volume><elocation-id>e0128560</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0128560</pub-id><pub-id pub-id-type="pmid">26030275</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vashlishan</surname><given-names>AB</given-names></name><name><surname>Madison</surname><given-names>JM</given-names></name><name><surname>Dybbs</surname><given-names>M</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Sieburth</surname><given-names>D</given-names></name><name><surname>Ch'ng</surname><given-names>Q</given-names></name><name><surname>Tavazoie</surname><given-names>M</given-names></name><name><surname>Kaplan</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An RNAi screen identifies genes that regulate GABA synapses</article-title><source>Neuron</source><volume>58</volume><fpage>346</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.02.019</pub-id><pub-id pub-id-type="pmid">18466746</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Bouhours</surname><given-names>M</given-names></name><name><surname>Gracheva</surname><given-names>EO</given-names></name><name><surname>Liao</surname><given-names>EH</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Sengar</surname><given-names>AS</given-names></name><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Roder</surname><given-names>J</given-names></name><name><surname>Boone</surname><given-names>C</given-names></name><name><surname>Richmond</surname><given-names>JE</given-names></name><name><surname>Zhen</surname><given-names>M</given-names></name><name><surname>Egan</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ITSN-1 controls vesicle recycling at the neuromuscular junction and functions in parallel with DAB-1</article-title><source>Traffic</source><volume>9</volume><fpage>742</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00712.x</pub-id><pub-id pub-id-type="pmid">18298590</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LT</given-names></name><name><surname>Chiou</surname><given-names>SS</given-names></name><name><surname>Liao</surname><given-names>YM</given-names></name><name><surname>Jong</surname><given-names>YJ</given-names></name><name><surname>Hsu</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Survival of motor neuron protein downregulates miR-9 expression in patients with spinal muscular atrophy</article-title><source>The Kaohsiung Journal of Medical Sciences</source><volume>30</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.kjms.2013.12.007</pub-id><pub-id pub-id-type="pmid">24751385</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rapid and precise engineering of the <italic>Caenorhabditis elegans</italic> genome with lethal mutation co-conversion and inactivation of NHEJ repair</article-title><source>Genetics</source><volume>199</volume><fpage>363</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1534/genetics.114.172361</pub-id><pub-id pub-id-type="pmid">25491644</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welton</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>W</given-names></name><name><surname>Kerr</surname><given-names>R</given-names></name><name><surname>Maxwell</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Differential expression of the muscarinic m2 acetylcholine receptor by small and large motoneurons of the rat spinal cord</article-title><source>Brain Research</source><volume>817</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(98)01208-6</pub-id><pub-id pub-id-type="pmid">9889370</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wertz</surname><given-names>MH</given-names></name><name><surname>Winden</surname><given-names>K</given-names></name><name><surname>Neveu</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>SY</given-names></name><name><surname>Ercan</surname><given-names>E</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy</article-title><source>Human Molecular Genetics</source><volume>25</volume><fpage>2168</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw084</pub-id><pub-id pub-id-type="pmid">27005422</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JG</given-names></name><name><surname>Southgate</surname><given-names>E</given-names></name><name><surname>Thomson</surname><given-names>JN</given-names></name><name><surname>Brenner</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>The structure of the ventral nerve cord of <italic>Caenorhabditis elegans</italic></article-title><source>Philosophical Transactions of the Royal Society B: Biological Sciences</source><volume>275</volume><fpage>327</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1098/rstb.1976.0086</pub-id><pub-id pub-id-type="pmid">8806</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiese</surname><given-names>S</given-names></name><name><surname>Pei</surname><given-names>G</given-names></name><name><surname>Karch</surname><given-names>C</given-names></name><name><surname>Troppmair</surname><given-names>J</given-names></name><name><surname>Holtmann</surname><given-names>B</given-names></name><name><surname>Rapp</surname><given-names>UR</given-names></name><name><surname>Sendtner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons</article-title><source>Nature Neuroscience</source><volume>4</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1038/83960</pub-id><pub-id pub-id-type="pmid">11175873</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Surmeier</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Muscarinic (m2/m4) receptors reduce N- and P-type Ca2+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway</article-title><source>Journal of Neuroscience</source><volume>16</volume><fpage>2592</fpage><lpage>2604</lpage><pub-id pub-id-type="pmid">8786435</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>J</given-names></name><name><surname>Pellizzoni</surname><given-names>L</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Sequence-specific interaction of U1 snRNA with the SMN complex</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>1188</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.5.1188</pub-id><pub-id pub-id-type="pmid">11867547</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Kitaoka</surname><given-names>S</given-names></name><name><surname>Egawa</surname><given-names>N</given-names></name><name><surname>Yamane</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>R</given-names></name><name><surname>Tsukita</surname><given-names>K</given-names></name><name><surname>Amano</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Morimoto</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>J</given-names></name><name><surname>Hosoi</surname><given-names>H</given-names></name><name><surname>Nakahata</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs</article-title><source>Stem Cell Reports</source><volume>4</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.02.010</pub-id><pub-id pub-id-type="pmid">25801509</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Rossoll</surname><given-names>W</given-names></name><name><surname>Wichterle</surname><given-names>H</given-names></name><name><surname>Singer</surname><given-names>RH</given-names></name><name><surname>Bassell</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Multiprotein complexes of the survival of motor neuron protein SMN with gemins traffic to neuronal processes and growth cones of motor neurons</article-title><source>Journal of Neuroscience</source><volume>26</volume><fpage>8622</fpage><lpage>8632</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3967-05.2006</pub-id><pub-id pub-id-type="pmid">16914688</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The liprin protein SYD-2 regulates the differentiation of presynaptic termini in <italic>C. elegans</italic></article-title><source>Nature</source><volume>401</volume><fpage>371</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/43886</pub-id><pub-id pub-id-type="pmid">10517634</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.20752.037</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hobert</surname><given-names>Oliver</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Columbia University</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Decreased SMN causes deleterious increases in neuronal M2 muscarinic receptors due to microRNA misregulation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>The authors harness the power of C.elegans genetics to interrogate the defects incurred by loss of SMN on neuromuscular function. Using a series of approaches, the authors implicate the worm ortholog of Gemin3 (<italic>mel-46</italic>), the miR-2 and the M2 muscarinic receptor. The study demonstrates the power of a genetically tractable system to understand fundamental biology. Based on their data and previously published work, the authors propose the following:</p><p>1) SMN-1 acts genetically through MEL-46/Gemin3. Molecularly, SMN-1 is necessary to achieve normal levels of MEL-46/Gemin3.</p><p>2) Normal levels of Gemin3 are necessary for correct miRNA processing/function, including <italic>mir-2.</italic></p><p>3) <italic>mir-2</italic> is necessary to repress <italic>gar-2</italic>. GAR-2 is an M2 receptor that is predicted to inhibit synaptic release at cholinergic NMJs and thus needs to be kept at relatively low levels for optimal NMJ function</p><p>These conclusions are based on a number of relatively indirect measures, which are for the most part not sufficient to support all claims. In essence, a number of qPCR experiments are required to support a number of conclusions. Specifically:</p><p>1) The authors propose that reduction of SMN-1 results in lower levels of MEL-46. This is based on one genetic interaction: the fact that <italic>mel-46</italic> overexpression rescues part of the defects observed in <italic>smn-1(lf)</italic> animals, most prominently, it suppresses the aldicarb resistance of <italic>smn-1(lf)</italic> animals. However, it does not rescue the pharyngeal defect of <italic>smn-1(lf)</italic>, suggesting some kind of tissue specificity. Since the connection to miRNA processing/function is given by MEL-46/Gemin3, I think it's important to provide a more direct link and the authors need to measure <italic>mel-46</italic> (RNA using qPCR and/or protein) in <italic>smn-1(lf)</italic>.</p><p>This is important given that an alternative explanation is not satisfactorily rejected. Specifically, the authors discard an effect of MEL-46 in stabilizing the maternal contribution of SMN-1 by quantifying GFP fluorescence from a very nice SMN-1::GFP allele generated with Cas9, over whole worms, in wt animals with or without MEL-46 overexpression. However, given that in all phenotypic assays the effect of MEL-46 is only seen in the <italic>smn-1(lf)</italic> background but not in the wt background, it is not clear if one would expect to see any changes in SMN-1 abundance in wt animals. A more direct test would have been to look at the remaining GFP in the <italic>smn-1(lf)</italic> progeny from heterozygous mothers and see whether this changes with overexpression of MEL-46. Also, given the tissue specificity observed phenotypically, it may be more revealing to focus e.g. on motorneurons. Although if levels are too low to see GFP, a western blot against GFP may already provide some information.</p><p>2) The connection of SMN to miRNAs through Gemin3 is solely based on previous publications reporting the dysregulation of certain miRNAs when SMN or Gemin3 are decreased. There is no direct connection in this work between this pathway and <italic>mir-2</italic>, the miRNA the authors find to be important for NMJ function. Based on the data provided, <italic>mir-2</italic> could be acting in the NMJs in a parallel pathway that has no connection to SMN-1 or MEL-46. To strengthen this link, the authors need to measure <italic>mir-2</italic> levels in <italic>smn-1(lf), mel-46</italic> mutants or overexpression strains. However, one has to wonder whether there is a connection at all: The authors claim to provide a link (although very indirect) with an epistasis analysis shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> where they look at a fluorescent reporter for <italic>gar-2</italic>, the predicted target of <italic>mir-2</italic>. The authors compare a reporter with the wt 3'UTR and one without the mir-2 binding site in wt animals or <italic>smn-1(lf)</italic>. In wt animals, the fluorescence ratio between the two reporters is ~1 and in <italic>smn-1(lf)</italic> animals it goes up by 5% (to 1.05). The authors suggest this is consistent with <italic>mir-2</italic> levels being lower in <italic>smn-1(lf)</italic> (because of lower mel-46/Gemin3, which is not shown) and that leads to <italic>gar-2</italic> derepression. In addition to this being an extremely small effect that would need additional data to be convincing (e.g. qPCR of <italic>gar-2</italic> mRNA in N2 v miR-2 mutant animals), there is a problem which is that the increase in ratio is not as one would expect from the reporter with the wt 3'UTR being derepressed (numerator going up) in <italic>smn-1(lf)</italic> but rather the reporter with the mutant 3'UTR is decreased in <italic>smn-1(lf)</italic> (denominator going down) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, panels C and D). There is no other connection provided between the effect that <italic>smn-1</italic> and <italic>mel-46</italic> may have on the NMJ and whatever function <italic>mir-2</italic> might have there as well.</p><p>3) The phenotypic and reporter analyses are consistent with <italic>gar-2</italic> being a target of <italic>mir-2</italic>. Given the small magnitude of repression observed, this point could be made more convincingly, for example by mutating the <italic>mir-2</italic> binding site in the 3'UTR of <italic>gar-2</italic>, which should not be too difficult given that the authors are able to generate alleles using Cas9.</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Decreased microRNA levels lead to deleterious increases in neuronal M2 muscarinic receptors in Spinal Muscular Atrophy models&quot; for further consideration at <italic>eLife</italic>. Your revised article has been favorably evaluated by a Senior Editor, a Reviewing Editor, and two reviewers.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>The authors have done a highly appreciated effort to incorporate the reviewers’ comments and suggestions and I think this has paid off in strengthening their model. However, one concern remains about a critical link in the story: The changes in <italic>mir2</italic> measurements (<xref ref-type="fig" rid="fig5">Figure 5</xref>), an important and good addition, needs to be done with better controls. Currently, the authors report <italic>mir-2</italic> levels relative to <italic>mir-60</italic> levels. This is another miRNA that might also be affected by the manipulations done in this experiment. It is not clear at all from looking at the raw data provided whether in these experiments <italic>mir-2</italic> is decreasing or <italic>mir-60</italic> is increasing, in fact the latter seems more supported by the data. There is also a problem of reproducibility in this experiment, with variances of &gt;10 Ct between replicates. It is strongly suggested that given the importance of this experiment, it should be repeated with additional normalization controls, which should include at least one non-miRNA RNA (U6, U18, 5S RNA). One suggestion for improving reproducibility is to use a remarkably well-working protocol published by Kien Ly, Suzanne J. Reid, Russell G. Snell as &quot;Rapid RNA analysis of individual <italic>Caenorhabditis elegans</italic>&quot; in MethodsX 2 (2015) 59-63.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.20752.038</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>[…] These conclusions are based on a number of relatively indirect measures, which are for the most part not sufficient to support all claims. In essence, a number of qPCR experiments are required to support a number of conclusions. Specifically:</italic> </p><p><italic>1) The authors propose that reduction of SMN-1 results in lower levels of MEL-46. This is based on one genetic interaction: the fact that mel-46 overexpression rescues part of the defects observed in smn-1(lf) animals, most prominently, it suppresses the aldicarb resistance of smn-1(lf) animals. However, it does not rescue the pharyngeal defect of smn-1(lf), suggesting some kind of tissue specificity. Since the connection to miRNA processing/function is given by MEL-46/Gemin3, I think it's important to provide a more direct link and the authors need to measure mel-46 (RNA using qPCR and/or protein) in smn-1(lf).</italic> </p><p><italic>This is important given that an alternative explanation is not satisfactorily rejected. Specifically, the authors discard an effect of MEL-46 in stabilizing the maternal contribution of SMN-1 by quantifying GFP fluorescence from a very nice SMN-1::GFP allele generated with Cas9, over whole worms, in wt animals with or without MEL-46 overexpression. However, given that in all phenotypic assays the effect of MEL-46 is only seen in the smn-1(lf) background but not in the wt background, it is not clear if one would expect to see any changes in SMN-1 abundance in wt animals. A more direct test would have been to look at the remaining GFP in the smn-1(lf) progeny from heterozygous mothers and see whether this changes with overexpression of MEL-46. Also, given the tissue specificity observed phenotypically, it may be more revealing to focus e.g. on motorneurons. Although if levels are too low to see GFP, a western blot against GFP may already provide some information.</italic> </p><p>We appreciate the reviewer’s criticism and the opportunity to show a more direct connection between SMN-1 and MEL-46. To confirm that loss of SMN-1 affects the function and/or levels of MEL-46, we have now generated two independent integrated lines expressing MEL-46 tagged with GFP behind the control of the cholinergic-specific <italic>unc-17</italic> promoter (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Using these, we were able to evaluate the effects of SMN-1 loss on MEL-46 levels and localization in cholinergic neurons. This seemed the most specific approach to quantify the effect of SMN-1 loss on MEL-46 in motor neurons. After crossing both independent integrated lines into the <italic>smn-1(ok355</italic>) background, we found an obvious defect in MEL-46 localization in dorsal cord motor neurons processes. We find that MEL-46::GFP in wild type control animals is sparsely localized to punctate structures along the dorsal cord (see <xref ref-type="fig" rid="fig2">Figure 2C</xref>). These structures are likely similar to axonal granules containing MEL-46, which have been reported in mammalian tissue culture studies (Todd et al., 2010a; Todd et al., 2010b; Zhang et al., 2006). In <italic>smn-1(ok355</italic>) animals, MEL-46::GFP is found in many more granules, with an average decrease in MEL-46::GFP fluorescence within granules (<xref ref-type="fig" rid="fig2">Figures 2B</xref>-<xref ref-type="fig" rid="fig1">1D</xref>). MEL-46::GFP mislocalization and decreased intra-granule levels in <italic>smn-1(ok355)</italic> cholinergic neurons support our model in which MEL-46 function is perturbed when SMN-1 levels decrease.</p><p>Unfortunately, we were unable to directly evaluate levels of maternally-loaded SMN-1::GFP in <italic>smn-1(ok355)</italic> homozygous animals. The simplest strategy would be to tag the endogenous <italic>smn-1</italic> gene on the balancer chromosome used to propagate <italic>smn-1(ok355).</italic> Using the CRISPR-based approach outlined in the manuscript and suggested by the reviewer, we attempted to GFP-tag endogenous <italic>smn-1</italic> on balancer chromosomes <italic>hT2</italic> and <italic>ccIs425</italic>. We were unsuccessful after multiple attempts. Therefore, we cannot unequivocally conclude that increased MEL-46 does not lead to increased stabilized maternally-loaded SMN-1. We make this caveat clear in the revised text (see “changes made to text” below). Given the severe MEL-46 localization defects we observe in <italic>smn-1(ok355)</italic> animals, however, it is more likely that increased MEL-46 proteins levels ameliorate <italic>smn-1(ok355)</italic> defectsby increasing MEL-46 within critical granules in motor neurons, like those in the dorsal cord. See <xref ref-type="fig" rid="fig2">Figures 2A-D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>.</p><p>Changes made to text for Editor Point 1:</p><p>“MEL-46 might act together with or downstream of SMN-1 in pathways necessary for NMJ function. […] Our findings suggest that SMN-1 impairs MEL-46 function, which could contribute <italic>to smn-1(ok355)</italic> synaptic defects (Dimitriadi et al., 2016).”</p><p>“Using the same CRISPR-based method, we were unable to tag endogenous <italic>smn-1</italic> on balancer chromosomes necessary for maintaining the <italic>smn-1(ok355)</italic> line. […] Therefore, although we cannot rule out stability of maternally-loaded SMN-1 as a contributing factor, the large effect that decreased SMN-1 has on MEL-46 localization favors a mechanism in which MEL-46 overexpression rescues <italic>smn-1(ok355)</italic> defects, at least in part, by restoring MEL-46 functional deficits in this background.”</p><p><italic>2) The connection of SMN to miRNAs through Gemin3 is solely based on previous publications reporting the dysregulation of certain miRNAs when SMN or Gemin3 are decreased. There is no direct connection in this work between this pathway and mir-2, the miRNA the authors find to be important for NMJ function. Based on the data provided, mir-2 could be acting in the NMJs in a parallel pathway that has no connection to SMN-1 or MEL-46. To strengthen this link, the authors need to measure mir-2 levels in smn-1(lf), mel-46 mutants or overexpression strains. However, one has to wonder whether there is a connection at all: The authors claim to provide a link (although very indirect) with an epistasis analysis shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> where they look at a fluorescent reporter for gar-2, the predicted target of mir-2. The authors compare a reporter with the wt 3'UTR and one without the mir-2 binding site in wt animals or smn-1(lf). In wt animals, the fluorescence ratio between the two reporters is ~1 and in smn-1(lf) animals it goes up by 5% (to 1.05). The authors suggest this is consistent with mir-2 levels being lower in smn-1(lf) (because of lower mel-46/Gemin3, which is not shown) and that leads to gar-2 derepression. In addition to this being an extremely small effect that would need additional data to be convincing (e.g. qPCR of gar-2 mRNA in N2 v miR-2 mutant animals), there is a problem which is that the increase in ratio is not as one would expect from the reporter with the wt 3'UTR being derepressed (numerator going up) in smn-1(lf) but rather the reporter with the mutant 3'UTR is decreased in smn-1(lf) (denominator going down) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, panels C and D). There is no other connection provided between the effect that smn-1 and mel-46 may have on the NMJ and whatever function mir-2 might have there as well.</italic> </p><p>We thank the reviewers for these suggestions. The work we have consequently done with qPCR analysis of miR-2 and <italic>gar-2</italic> transcripts greatly strengthens the manuscript. We focused specifically on how decreasing SMN-1 or MEL-46 within neurons impacts mature miR-2 levels and <italic>gar-2</italic> mRNA levels. To do this, we undertook RNAi studies using animals sensitive to RNAi by feeding only in neurons (Calixto et al., 2010). These animals were placed on bacteria expressing SMN-1 or MEL-46 RNAi constructs for at least two generations. We found that knock-down of either SMN-1 or MEL-46 resulted in a large (~80%) decrease in miR-2 levels. These results are consistent not only with a role for both SMN-1 and MEL-46 in miR-2 biogenesis, but further suggest a relationship between SMN-1 and MEL-46 in a pathway important for proper miRNA function. In measuring <italic>gar-2</italic> transcript from these samples, we found that this decrease in miR-2 levels did not result in significantly increased <italic>gar-2</italic> mRNA levels. This was unsurprising as <italic>gar-2</italic> mRNA levels were also not significantly increased in <italic>mir-2(gk259)</italic> loss of function animals compared to N2 control animals (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Previous reports have found that changes in miRNA levels do not necessarily result in changes in target transcript levels. Instead, miRNAs may bind their targets and inhibit translation without transcript destabilization (Cloonan, 2015; Selbach et al., 2008). Overall, these data support our model and further suggest that SMN-1 and MEL-46 not only impact miRNA activity, but may play a role in miRNA biogenesis.</p><p>See <xref ref-type="fig" rid="fig4">Figure 4I</xref> and <xref ref-type="fig" rid="fig5">Figures 5B-C</xref>.</p><p>Changes made to text for Editor Point 2:</p><p>“We also assessed the effect of miR-2 loss on <italic>gar-2</italic> transcript levels and found no significant difference in <italic>gar-2</italic> mRNA levels between wild type animals and <italic>mir-2(gk259)</italic> loss of function animals (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). […] Previous studies have reported that miRNAs can influence protein synthesis of targets without destabilizing mRNA levels (Cloonan, 2015; Selbach et al., 2008).”</p><p>“Increased GAR-2 translation in animals lacking SMN-1 might be due to decreased mature miR-2 levels. […] These results suggest neuronal miR-2 levels are decreased when MEL-46 or SMN-1 levels decrease.”</p><p><italic>3) The phenotypic and reporter analyses are consistent with gar-2 being a target of mir-2. Given the small magnitude of repression observed, this point could be made more convincingly, for example by mutating the mir-2 binding site in the 3'UTR of gar-2, which should not be too difficult given that the authors are able to generate alleles using Cas9.</italic></p><p>We agree. CRIPSR/Cas-9-based genome editing was used to scramble the microRNA binding site in the <italic>gar-2</italic> 3’UTR. Animals with a scrambled endogenous miR-2 binding site in the <italic>gar-2</italic> 3’UTR were resistant to aldicarb, when compared to control animals (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Furthermore, animals with the scrambled binding site in the <italic>gar-2</italic> 3’UTR had increased levels of <italic>gar-2</italic> messenger RNA (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These results strengthen the model in which <italic>gar-2</italic> is a direct target of miR-2. This result is perplexing, however, since <italic>mir-2(gk259)</italic> animals did not have significantly increased <italic>gar-2</italic> transcript levels. We note that other miR-2 family members likely bind this site, including miR-43, miR-250, and miR-797. Additionally, our qPCR results come from whole animal lysate. Thus, the increase in <italic>gar-2</italic> messenger RNA likely results from the inability of all miR-2 family members to bind the <italic>gar-2</italic> 3’UTR throughout all tissues. These family members may act differently than miR-2, resulting in transcript destabilization when bound. Furthermore, since miR-2 appears to be limited to the nervous system, the effect it has on <italic>gar-2</italic> transcript in neurons may be minimized by levels of the more broadly-expressed <italic>gar-2</italic> transcript. This may explain why a significant difference in transcript levels is seen when the binding site is scrambled, but not in <italic>mir-2(gk259)</italic> loss of function animals.</p><p>See <xref ref-type="fig" rid="fig4">Figure 4B-C</xref> and <xref ref-type="fig" rid="fig4">Figure 4H</xref>.</p><p>Changes made to text for Editor Point 3:</p><p>“To determine if miR-2 regulates GAR-2 expression directly, we examined the consequences of perturbing the putative miR-2 binding site in the <italic>gar-2</italic> 3’UTR. […] Disruption of the 3’UTR site likely inhibits binding of other miR-2 family members, likely contributing to the effect we observe (Ibanez-Ventoso et al., 2008).”</p><p>[Editors' note: further revisions were requested prior to acceptance, as described below.]</p><p><italic>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</italic> </p><p><italic>The authors have done a highly appreciated effort to incorporate the reviewers’ comments and suggestions and I think this has paid off in strengthening their model. However, one concern remains about a critical link in the story: The changes in mir2 measurements (<xref ref-type="fig" rid="fig5">Figure 5</xref>), an important and good addition, needs to be done with better controls. Currently, the authors report mir-2 levels relative to mir-60 levels. This is another miRNA that might also be affected by the manipulations done in this experiment. It is not clear at all from looking at the raw data provided whether in these experiments mir-2 is decreasing or mir-60 is increasing, in fact the latter seems more supported by the data. There is also a problem of reproducibility in this experiment, with variances of &gt;10 Ct between replicates. It is strongly suggested that given the importance of this experiment, it should be repeated with additional normalization controls, which should include at least one non-miRNA RNA (U6, U18, 5S RNA). One suggestion for improving reproducibility is to use a remarkably well-working protocol published by Kien Ly, Suzanne J. Reid, Russell G. Snell as &quot;Rapid RNA analysis of individual Caenorhabditis elegans&quot; in MethodsX 2 (2015) 59-63.</italic> </p><p>We thank the reviewer for these suggestions. We undertook the additional experiments suggested by the reviewer. We increased the number of samples from 3 to 6 for each group and examined miR-2 expression levels relative to 3 different RNAs: a microRNA (miR-60), a ribosomal RNA (18S), and a messenger RNA <italic>(act-1).</italic> After either <italic>mel-46</italic> and <italic>smn-1</italic> RNAi treatments, we observed decreased miR-2 levels, normalized to any of these 3 RNAs relative to empty RNAi (<xref ref-type="fig" rid="fig5">Figure 5B</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>). In the revised manuscript, we report miR-2 levels relative to miR-60 levels in the main figures and include miR-2 levels relative to <italic>act-1</italic> and 18S rRNA in the supplementary figures (Martinez et al., 2008). We utilized previously reported amplification primers for both 18S rRNA (Essers et al., 2015) and <italic>act-1</italic> (Ly et al., 2015). This extended analysis makes clear that miR-2 levels decrease when <italic>smn-1</italic> or <italic>mel-46</italic> function decreases.</p><p>Choosing an appropriate control RNA can be challenging; here we examined 3 different possibilities. We evaluated the stability of each of the putative “control RNAs” under the different experimental conditions using the “model-based approach to estimation of expression variation” (Andersen et al., 2004). This mathematical model is used to describe the “stability value” of candidate genes- taking in account variability within a group of samples under the same treatment conditions and between groups of samples under different treatment conditions. Lower “stability values” for a given group of genes indicate more stable expression. We find that miR-60 is the most stable RNA (stability value = 0.250), compared to 18S rRNA or <italic>act-1</italic> (0.316 and 0.376, respectively). As miR-60 is the most stable candidate, we use it as a control in the main text figures.</p><p>See <xref ref-type="fig" rid="fig5">Figures 5B</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>.</p><p>Changes made to text for Editor Point 1:</p><p>“After neuron-specific RNAi knock-down of either SMN-1 or MEL-46, we found decreases in mature miR-2 levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>), but no change in <italic>gar-2</italic> transcript levels (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).”</p><p>“Primer sequences for <italic>act-1</italic>: 5’-acgccaacactgttctttcc-3’ and 5’-gatgatcttgatcttcatggttga-3’ (Ly et al., 2015). Primer sequences for 18S rRNA: 5’-TTGCTGCGGTTAAAAAGCTC’3’ and 5’-CCAACCTCAAACCAGCAAAT-3’ (Essers et al., 2015). The stability of miR-60, 18S rRNA, and <italic>act-1</italic> housekeeping RNAswere evaluated using the ‘model-based approach to estimation of expression variation’ (Andersen et al., 2004).”</p><p>“miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty<italic>(RNAi), smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals relative to housekeeping miRNA miR-60. <italic>t-</italic>test, two-tailed (n=6 for each condition).”</p><p>“(C) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty<italic>(RNAi), smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals relative to housekeeping gene <italic>act-1</italic>. […] Quantification of mature miR-2 for empty<italic>(RNAi), smn-1(RNAi)</italic>, and <italic>mel-46(RNAi)</italic> young adult animals relative to housekeeping rRNA 18s. <italic>t-</italic>test, two-tailed (n=6 for each condition).”</p></body></sub-article></article>